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 Background: As discussed within the guidelines from the American Society of  
Health-System Pharmacists (ASHP), pharmacists are an integral part of the hospice 
multidisciplinary team involved in optimizing the treatments. Methadone, a long-active 
opioid, is particularly useful in this population but may be clinically underutilized. 
Additionally, the cost share of medication utilization in hospice and palliative care is shifting 
towards hospice providers. The assessment of medication utilization and methadone use in this 
setting can help develop overall cost/clinical optimization strategies. Thus, there is a need to 
understand the use and expenditure of various medications and pharmacists' role in 
providing methadone use recommendations in hospice and palliative care settings that 
would facilitate the cost containment.  
Objectives: The purpose of the study was to (1) identify the prevalence and acceptance of 
clinical pharmacists’ methadone recommendation before and after admission to 
hospice/palliative care, and (2) identify the frequency, expenditure, and monthly mean cost 
of therapeutic medication classes belonging pain, pulmonary and anticoagulant 
medications categories.  
 v 
Methods: The study was conducted in two phases. The phase I was conducted in two parts 
of data collection at DeltaCareRx hospice and palliative care site. A systematic literature 
review formed the basis of clinical pharmacist's role and significance in the 
multidisciplinary team of hospice and palliative care. The instruments for data collection 
were developed for the clinical pharmacists and student pharmacist researcher. Descriptive 
and inferential statistics of the collected data identified the prevalence of clinical pharmacist 
recommendations for methadone upon admission to hospice/palliative care and the acceptance 
of the pharmacists’ recommendations for methadone after admission to hospice/palliative care. 
Phase II studied medication utilization at the hospice/palliative sites served by the pharmacy 
benefit manager (PBM) DeltaCareRx. Pharmacy claims data for six months of the year 2019 
was obtained from DeltaCareRx. The data included information on the utilization of individual 
medications and their associated therapeutic classes, patient characteristics, and dispensing 
cost charged to the patients. Claims data were analyzed to identify the frequency in use, total 
expenditure, and the monthly average cost of each therapeutic class and the pattern in the 
utilization of therapeutic class based on the sex of the patients. The consumption of individual 
medications was calculated using defined daily doses (DDD), a methodology that analyses 
medication consumption and enables comparison across different months in a standardized 
manner.  
Results: In total, the data collected on both instruments included 158 (99.3%) patients. The 
prevalence of pharmacist methadone recommendation was 37 (23.4%). The majority (26; 
16.5%) of methadone recommendation were for switching to methadone as the maintenance 
treatment. Out of the 37 pharmacist recommendations, 5 (13.5%) were accepted by the 
physicians, and the physicians themselves implemented 3 (8.1%) recommendations. In phase 
II, the pharmacy claims data were obtained for six months (January, June, July, September, 
October, and November) of 2019. The data consisted of 487 unique therapeutic classes and 
3,189 unique medications. Sympathomimetics, opioid agonists, and coumarin anticoagulants 
were the most frequently used therapeutic classes. The average cost per male/female patients 
was the highest ($64.82 and $67.70) for pulmonary medications. Medications such as albuterol, 
enoxaparin, and morphine had higher consumption levels.   
Conclusion: The study provided valuable insights regarding clinical pharmacists' significant 
role in hospice and palliative care. A pharmacist's role in providing recommendations on 
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medication use to the patients can improve clinical/cost optimization in the setting. The data 
collection on pharmacists’ recommendations on methadone demonstrates minimum 
medication use in the hospice and palliative care setting. There should be an increase in the use 
of this cost-effective medicine for pain management among the patients. The pharmacy claims 
data analysis implements that the rise in use of cost-effective medications from the individual 
therapeutic classes will help in higher cost savings at DeltaCareRx’s client sites and reduce the 
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CHAPTER 1: BACKGROUND 
I. Hospice and palliative care  
 
a. Definition and prevalence 
 
Hospice is compassionate care for patients who are in their terminal phase of life, defined as less than six 
months by the Medicare program.1 It includes mainly pain and symptom management, and providing 
emotional and spiritual support as per the patient’s needs. Palliative care is defined by World Health 
Organization (WHO) as “a service which improves quality of life of patients through by means of early 
identification and impeccable assessment and treatment of pain and other problems, physical, 
psychosocial and spiritual”.2  
 
Hospice and palliative care services are paid for through both public and private insurance plans in the 
United States (US). For patients in the Medicare program, hospice is covered by Part A (Hospital 
Insurance) under the Medicare Hospice Benefit, established in 1982.  Beneficiaries are eligible for the 
hospice benefit only if the hospice provider and their regular provider certify that the beneficiary is 
terminally ill (defined as a life expectancy of less than six months). Hospice care coverage for Medicaid 
patients depends on the life expectancy period established by the respective state in which they reside.3 
Palliative care is covered for beneficiaries under Medicare Part B (Medical Insurance). Medicaid patients 
can avail some palliative coverage as well, depending on the treatment they receive. Patients who are not 
eligible for hospice services due to a life expectancy of more than six months qualify for palliative care 
service.  
 
Medicare defines four levels/types of hospice care, which varying needs of the patients. The first level of 
care is Routine Hospice Care (RHC) which is provided at the patient’s residence, also known as routine 
nursing home care. The second level of care is Continuous Hospice Care (CHC), which is predominantly 
nursing care that focuses on maintaining pain control or addressing symptom crisis situations at the 
patient’s home. The third level of care is Inpatient Respite Care (IRC), which provides a temporary support 
to the patient’s primary caregiver. It can be offered in various settings, such as the hospital, hospice 
facility, or a long-term care facility that has enough 24-hour nursing personnel present. The fourth level 
of care is General Inpatient Care (GIP) which is offered for pain control or other acute symptom 
management that cannot feasibly be supplied in any other setting. GIP is offered when an additional care 
is required for managing symptoms of the patients. Among all levels of care, RHC service is the most 
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utilized type. In 2017, among all the hospice care in US, 98.2% of days of care were provided at RHC 
level, compared to CHC (0.2%), IRC (0.3%) and GIC (1.3%).4,5 
 
In 2017, National Hospice and Palliative Care Organization (NHPCO) reported that 1.49 million Medicare 
beneficiaries received hospice care services, an increase of 4.5% from 2016.4,5 The proportion of enrollees 
under Medicare Advantage plans who utilized hospice benefits have drastically increased from 26.8% in 
2012 to 34.7% in 2017. This has resulted in a $18.99 billion payment by Medicare to hospice care 
providers in 2017, a 6.3% increase compared to $17.86 billion paid in 2016. The maximum spending 
based on level of care was on RHC service at 89.31%, and lowest on CHC at 1.77% of total spending.5  
 
In case of palliative care services, fast growth has been observed as well. One of the reasons for this is the 
ability of palliative care services to improve quality of life (QoL) for both patients and their families. In 
2019, 72% of hospitals with 50 or more beds were identified to have a palliative team, compared to 67% 
in 2015.6,7  A report published by the Center to Advance Palliative Care (CAPC) assigned a letter grade 
(A to F) to almost all the states in the US as per the number of beds in the hospital and availability of a 
palliative care team in the same hospital. The letter grading rubric applied includes: “A grade is assigned 
to a state in which over 80% of hospitals had palliative care programs, B grade to states with 61%–80% 
of hospitals with palliative care programs, C grade to states with 41%–60% of hospitals having palliative 
care programs, D grades to states with 21%–40% of hospitals having palliative care programs, and F 
grades to states with 20% or fewer hospitals having palliative care programs”.7 As per the grading, three 
quarters of states in the US have either A or B grade, with more than 60% of hospitals with a palliative 
care team. The percentage of annual hospital admissions for palliative care increased slightly from 5.0% 
in 2016 to 5.3% in 2017.7 The availability of palliative care depends on geography of the hospital and 
hospital size in terms of number of beds and tax status. Tax status is the predictor of access to palliative 
care. In 2019, as per the proportion of hospitals with palliative care based on tax status. Nonprofit hospitals 
regardless of hospital size (i.e.  hospital beds facility 50-150, 151-300 and 301-350) were found to have 
higher proportion of palliative care services available.  Access to palliative care was lowest for the for 
profit hospitals.8 
b. Clinical importance 
 
Hospice and palliative care focus on relieving pain and other symptoms in patients. The services offered 
in hospice setting focus on improving patient’s remaining time left by providing comfort. Care 
additionally aids patients’ families and caregivers during the time of illness by providing a support system. 
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One of the main aspects the care revolves around is providing quality of life to all the patients. All of the 
patient’s needs are addressed during the time of illness, including physical, social, physiological and 
spiritual. 2 
Hospice improves end-of-life outcomes. The link between hospice care services and outcomes was 
identified through a research study, “Quality of life matters: end of life care news and clinical findings for 
physicians,” with data acquired from the Dartmouth Atlas of Healthcare Report (2012) and the American 
Hospital Association Survey (2012). It found that hospice care service was associated with high values of 
end-of-life care outcomes such as less hospital deaths (p=0.01), hospital stays (p=0.01), better pain control 
(p=0.01) and good patient ratings (P=0.01).9  
Unlike hospice care, palliative care does not depend on prognosis of terminal illness. It mainly focuses on 
symptom management and psychological support. It achieves the desired clinical outcomes by 
comprehensive assessment and treating patient’s physical, psychological, and spiritual symptoms. 
Palliative care plays a role in decreasing symptom burden, increasing communication between 
multidisciplinary teams and improving patient’s treatment regimen. Initiating early palliative care in 
cancer patients has shown improvement in quality of life,10,11 symptoms11,12 and survival rates. 12,13 
c. Costs within the healthcare system 
 
In 2017, 1.5 billion Medicare beneficiaries received hospice services, with a dramatic increase in resources 
utilized from $2.9 billion in 2000 to $17.9 billion in 2017.14 Hospice and palliative care costs are shared 
by multiple entities, including Medicare, Medicaid, managed care or private insurance and other (such as 
charity and self-pay). The cost breakdown for each of these entities is 85.4%, 5%, 6.9% and 2.7% of the 
total expenditure, respectively.15 
 
Medicare patients receive hospice coverage through their Medicare advantage plan. Payments are made 
from Medicare to hospice providers in a form of daily rates. As soon as a patient is enrolled in the hospice 
setting, the providers receive a fixed amount payment from Medicare, based on the four levels of care. 
For 2019, RHC for days 1-60 has a base rate of $196 per day and days 61+ has a base rate of $145, while 
CHC is $42 per hour, IRC is $176 per day and GIC is $758 per day.14 The payment rates are changed 
annually by the inpatient hospice market basket index. The rate for the most common level of hospice 
care, RHC, was reformed in 2016 by CMS.16,17 Originally, RHC was paid at a single rate, but now 
Medicare pays two per diem rates for RHC that includes a higher rate for the first 60 days of a hospice 
episode and a lower rate for days 61+, at $196 and $154 per day, respectively, in 2019.16  The change in 
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the payment rates were made because hospices provide maximum care during the beginning and end of 
the episode and less during the middle phase.   
 
Medicare pays the hospice/palliative care provider as per diem rate for the assigned level of care provided. 
The payment is fixed is regardless of the service provided to the patients.18 Additionally, the payments 
are designed to limit the costs. An overall cap on the aggregate payment is applied to the Medicare hospice 
reimbursements along with caps on inpatient cap to limit the  number of inpatient days.19 
 
Hospice care services has proven to be cost effective compared to the care acquired in a hospital during 
the patient’s last 180 days of survival, with the per diem expenditure in the inpatient setting far exceeding 
that for palliative/hospice care.20 A cost-effectiveness study was conducted to evaluate the cost savings 
due to palliative inpatient admissions. The results of this study showed it to be more cost effective than 
the standard/usual inpatient care service in the hospital.21 A retrospective data analysis of Medicare claims 
data demonstrated that beneficiaries enrolled in hospice 53–105 days before death saved $2,561 compared 
to a matched, nonhospice control population ($22,083 vs $26,466 p<0.01).22 
 
II. Medication use in hospice setting 
 
Beneficiaries covered under Medicare Hospice Benefit receive treatment to address symptoms, maximize 
comfort and improve quality of life. Under Medicare Part A, beneficiaries have access to only those drugs 
that are used for pain relief and other terminal illness conditions (inclusive of biologics which have 
palliative roles). Hospices utilize formularies, wherein all commonly used drugs for palliation and 
terminal illness management are included.  
a. Policy changes with Medicare billing 
 
There are instances when beneficiaries require medications not on the hospice formulary and/or covered 
by Part A. In this case, previous Medicare guidelines allowed inappropriate payments for these 
medications required to treat hospice related symptoms under the Medicare Part D benefit. However, in 
2013, policy was changed to prevent these inappropriate payments. The letter stated that drugs and 
biologics when used primarily for the relief of pain and symptom control related to the terminal condition 
will be covered under the Medicare Part A per-diem payment. The medication will be covered under Part 
D only when it is not related to the patient’s terminal illness.23  
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III. General role of pharmacists 
 
Pharmacists are highly educated with regards to medications. They conduct comprehensive medical 
history reviews and perform medication reconciliation. Special attention is given to pharmacotherapy 
history, symptom assessment, and identification of drug-related problems. Pharmacists also provide 
patient counseling where they can identify inadequate treatment response or treatment-related adverse 
events.24 In 2010, CMS published a certification process manual for hospice providers, recommending 
that each hospice care facility have a clinical pharmacist. The functions carried out by this pharmacist 
may include educating and training patients regarding drug management and assisting patients in 
treatment selection. They can also conduct outcome assessment for ensuring the quality of the service 
provided. They play a significant role in managing adverse effects and proving recommendation wherever 
necessary.25  
 
The 2000 American Society Health System Pharmacist guidelines detailed pharmacist responsibilities and 
their scope of practice in contributing to the hospice care.26 The listed roles of pharmacist included: (1) 
symptom management, (2) counseling and education of staff and family members, (3) ensuring adherence 
to the drug, (4) addressing financial concerns of the patients and (5) disposal of medication after patient’s 
death. Further, ASHP published an updated report exploring extended involvement of the pharmacist in 
hospice and palliative care (PHC)27. It describes PHC services in two parts, including essential and 
desirable services. Roles and responsibilities for essential services include: (1) direct patient care, (2) 
medical review and reconciliation, (3) education and medication counseling and (4) administrative roles. 
Desirable services include: (1) direct patient care, (2) education, (3) scholarship and (4) administrative 
roles. 
 
IV. Pain management within hospice/palliative care 
 
Pain is a multidimensional experience of emotional and physical dimensions. The concept of total pain 
for terminally ill patients is made up of four components, including: (1) physical noxious stimuli, (2) 
emotional discomfort, (3) interpersonal conflicts, and (4) nonacceptance of one’s own dying.28 The 
ultimate key of pain management in end-of-life care is pain assessment. They focus on not only treating 
physical pain but also the emotional and interpersonal pain of the patient. The objective of end of life care 
is assisting the patient with pain reduction interventions and improving their functioning abilities as much 
as possible. There are organizations such as National Hospice and Palliative Care Organization (NHPCO), 
American Academy of Hospice and Palliative Medicine (AAHMA) , Center to Advance palliative Care 
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(CAPC) and others which publish guidelines/reports which can be useful for delivering hospice and 
palliative care.29,30 
a. Clinical guidelines and outcomes of interest 
 
Pain is classified in an unstructured manner despite being a common ailment among patients. A task force 
on taxonomy initiated by International Association for Study of Pain (IASP) provides a detailed 
classification of chronic pain.31 It classifies chronic pain in two types; chronic primary pain and secondary 
pain. Chronic primary pain is characterized by disability or emotional stress, a more “nonspecific” pain. 
International Classification of Diseases 11th revision, “defines the universe of diseases, disorders, injuries 
and other related health conditions, listed in a comprehensive, hierarchical fashion”.32 Chronic secondary 
pain is more specific pain represented by ICD-11. Additionally, WHO guidelines on “Palliative care: 
symptom management and end of life care” explains pain management in detail.33 It recommends 
conducting pain assessment, assigning treatment based on the assessment and later on managing the 
symptoms due the treatments assigned. In 2017, the National Coalition for Hospice and Palliative Care 
published the ‘Clinical Practice Guidelines for Quality Palliative Care, 4th edition,’ aimed to improve 
palliative care access to patients with serious illness by guiding the healthcare organizations across to 
integrate principles in their routine assessment and delivery of quality care.29  
b. Medications used in pain management 
 
Pain management in an end-of-life care setting begins with determining the patient’s pain type. 
Assessment can be in terms of location of pain (visceral, somatic, neuropathic or nociceptive) or intensity 
of pain.34 Determination of the type of pain assists providers in assigning appropriate pharmacotherapy. 
WHO’s Pain Ladder provides guidelines for achieving pain management in cancer patients as well as 
patient with chronic and acute nonmalignant pain. The first line agents are non-opioids drugs such as 
acetaminophen and/or NSAIDS, used to treat mild type of pain. For treating moderate pain, the guidelines 
include administering an opioid such as hydrocodone or oxycodone along with or without 
acetaminophen/NSAID.35 Patients with severe pain are advised to use stronger opioid therapies, due to 
their analgesic effect.36 Some of the common opioid used in hospice care include morphine, 
buprenorphine, fentanyl, etc. An essential medication list for palliative care includes ibuprofen and 
morphine as a treatment for pharmacological pain management.37 
c. Utilization of methadone in hospice care  
 
Traditionally, methadone, a synthetic opioid, has been used for treating opioid dependence, but it also has 
significant utility in the treatment of chronic pain, where it has clinical and cost benefits over other opioids 
 7 
which are used for pain management.34,38 Methadone is considered to have a high bioavailability, long 
duration of action and is available in multiple dosage forms (oral, rectal, parenteral). 39 It also provides an 
option for treatment in patients with morphine allergy. Furthermore, it acts as a N-methyl-D-aspartate 
(NMDA) receptor antagonist, which provides utility in the treatment of neuropathic pain and a reduced 
propensity to develop opioid tolerance.40,41,42  
 
Methadone is a high-risk medication, which makes it important for its administration and use to be 
monitored closely by a pharmacist. The medication can cause several important adverse effects, including 
QTc interval prolongation, respiratory depression, and drug accumulation. The long half-life of the drug 
is the consequence of accumulation in the body relative to amount of drug eliminated from the body.43 
The American Pain Society (APS) and the College on Problems of Drug Dependence (CPDD), in 
collaboration with the Heart Rhythm Society (HRS), consulted an interdisciplinary panel to develop a 
clinical practice guideline on safer prescribing of methadone for treatment of opioid addiction and chronic 
pain. The guidelines recommend careful assessment and selection of patient prior to administering 
methadone, inclusive of patient education/counseling and a baseline ECG assessment.44,45 
d. Role of pharmacists specifically in pain management 
 
Pharmacists are a great source of timely advice to patients. They are available without appointments and 
at convenient locations to discuss any patient’s onset of pain episodes.46 A pharmacist-managed pain clinic 
resulted in a decrease in waiting for appointments and elimination of unscheduled visits for narcotic 
prescription. Their involvement resulted in close  monitoring of pharmacotherapy, adverse events, and 
medication dosages. Pharmacists helped in facilitating communication between pain clinic staff, 
pharmacy department and physicians.47 A systematic review and meta-analysis analyzed pharmacist role 
in chronic pain management at community and hospital settings. The identified roles included conducting 
medication reviews, specialized prescription delivery service, face to face consultation and providing 
recommendations to the physicians. These resulted in reduced pain intensity, improvement of physical 
functioning and patient satisfaction.48  
 
V. DeltaCareRx 
DeltaCareRx is a locally based pharmacy services organization that works with hospice and palliative care 
providers across the US. Duquesne University has a collaboration with the organization through Dr Mary 
Mihalyo, a clinical pharmacist faculty member in the School of Pharmacy.  
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a. Description of the organization 
 
DeltaCareRx is a pharmacist-founded, pharmacist-owned, and pharmacist-operated pharmacy benefit 
management (PBM) company that works exclusively with and for hospice and palliative care providers, 
primarily community-based, not-for-profit hospice and palliative care organizations. Pharmaceutical care 
is provided through their mail order pharmacy and a nationwide network of highly regarded local retail 
pharmacies. DeltaCareRx has a mission to transform and improve the hospice pharmacy industry through 
business transparency, innovation, consistent customer service and community pharmacy relationships. 
The transparency is maintained through the creation of pricing models and innovative technologies 
designed to support clinicians. Furthermore, the organization is known for delivering quality, 
compassionate, cost-effective pharmaceutical care for patients with a life-limiting diagnosis.49 
b. Services provided to hospices 
 
DeltaCareRx provides local PBMs services to hospices. It facilitates medication availability from local 
pharmacies and optimizes cost-effectiveness. Additionally, they provide a facility known as inpatient 
innovation™ which is a Delta Care pharmacy installed in an inpatient unit. Mail order delivery is provided 
to the patient’s house which is useful in case of medical crisis. They provide patient monitoring through 
their branch of service known as ADAPT (remote patient monitoring and, pharmaceutical care at home). 
It is created for remote patient monitoring and proving pharmaceutical care at home. ADAPT delivers 
therapeutic expertise, prescription dispensing options and technological innovation to improve clinical 
outcomes and effective cost control mechanisms. Additionally, report generation is made easy through 
their innovative web-based technology Deltalytics. These reports assist in understanding trends in 
prescription, matching benchmarking values and quality initiatives. They provide their clients with newest 
technology, education support and cost containment strategies.  
 
VI. Problem statement 
 
Pharmacists play an important role  in hospice and palliative care. Their involvement in pain management 
has demonstrated desired clinical and cost outcomes. Despite many advantages of pharmacist’s 
involvement and recommendations by ASHP, many hospice and palliative care organizations remain 
reluctant to include pharmacist in their multidisciplinary team. The practical demonstration of importance 
of a pharmacist recommendation and their role will make the idea of adding a pharmacist to the team 
stronger. Therefore, it is necessary to assess their involvement in the daily routine of hospice and palliative 
care. Their involvement can be assessed through the recommendation they provide to the patients 
 9 
suffering with pain. Methadone is an effective medication to treat chronic pain and generates cost savings. 
Still it is found to be  underutilized in hospice and palliative care settings. Therefore, it is necessary to 
understand whether pharmacist recommend this drug for pain management. If the provided 
recommendations have not been accepted by the physicians without a reason, it  would demonstrate  a 
gap in knowledge transfer regarding the appropriate use of the medication. One of the opportunities to 
understand the trend in use of methadone at hospice and palliative care sites is through Deltalytics. It is a 
web- based report generator innovated by  DeltaCareRx. The reports generated contains the utilization 
value of each medication for each one of the DeltaCareRx’s clients. These values are then compared to 
the industry benchmarking. This activity decreases unnecessary utilization of medication and encourages 
cost saving. Analyzing the reports would assist in understanding  the pattern in use of methadone and 
other medications post the Medicare policy changes in 2013. Additionally, it will encourage  the use of 
cost-effective drugs at the client sites.  
 
VII. Study objectives/aims 
 
Therefore, to further understand the importance and impact of pharmacist services in hospice/palliative 
care, the specific aims of the studies are as follows: 
 Identify the impact of clinical pharmacist recommendations for methadone upon admission to 
hospice/palliative care services 





























ASHP guidelines describe the expansion of the clinical pharmacist roles in hospice and palliative care 
service.27 Clinical pharmacists play different roles in patient counseling, optimizing medication use, and 
recommending or terminating medications in the provision of care.26,50 The inclusion of a pharmacist in 
the hospice/palliative care has potential to improve clinical outcomes and demonstrate cost savings.51 
 
Pharmacists are involved in direct contact of care in pain management given their accessibility compared 
to other healthcare professionals. Clinical pharmacists can conduct clinical pain assessments before and 
after administration of the treatment. They also can play an important role while selecting and monitoring 
appropriate therapeutic regimens for patients. Valgus et al. evaluated the impact of a pharmacist-led, 
interdisciplinary team intervention on cancer patients in an ambulatory cancer clinic setting. The 
intervention was found to improve symptom scores and use of medications in these patients.52 A 
pharmacist is also an integral part of educating/training other staff members and family members. A 
systematic review and meta-analysis conducted by Benneth et al. reported the positive impact of 
pharmacist-led educational interventions on chronic pain patients.53 As per the ASHP guidelines, roles 
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and responsibilities of a pharmacist in a hospice and palliative care multidisciplinary team can assist in 
improving patient’s quality of life.27  
 
There are many studies that have provided information on roles of a pharmacist in hospice and palliative 
care settings. However, the specific impact of clinical pharmacists in pain management in these settings 
has not been fully evaluated. Accordingly, it is necessary to identify the impact of pharmacist-led 
interventions or pharmacist involvement on clinical/cost outcomes in the treatment of pain in hospice and 
palliative care.  
 
II. Objective  
 
The objective of the systematic review was to: (1) identify available information on the extent of clinical 
pharmacist involvement in the pain management of hospice and palliative care patients, and (2) explore 
relevant roles of a pharmacist in achieving clinical/cost outcomes while participating in pain management 
of end-of-life care patients.  
 
III. Search strategy  
 
The systemic review was conducted using the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines.54 The articles were retrieved/assessed on three databases: PubMed, 
Embase and Scopus. The first search was done on PubMed using keywords including ‘pharmacist,’ 
‘hospice care,’ ‘palliative care,’ ‘pain’ and ‘pain management.’ The search strategy from PubMed was 
then modified to suit Embase and Scopus search strategies. The keywords utilized in all the three databases 




((("Pharmacists"[Mesh] OR Pharmacist*[tiab] OR Pharmacist*[ot] OR "Pharmacy Service, 
Hospital"[Mesh] OR "Pharmacy Service”[tiab] OR "Pharmacy Service”[ot] OR "Pharmacist service"[ot] 
OR "Pharmacist service"[tiab])  
AND  
("Pain"[Mesh] OR "Pain"[ot] OR "Pain"[tiab] OR "Pain Management"[Mesh] OR "Pain 
Management"[tiab] OR "Pain Management"[ot] OR “Hospice and palliative Care Nursing”[MeSH] OR 
“Analgesics”[Mesh] OR Analgesic*[tiab] OR Analgesic*[ot])  
AND  
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("Hospice Care"[Mesh] OR "Respite Care"[Mesh] OR "Respite Care"[ot] OR "Respite Care"[tiab] OR 
"Home Care Services"[Mesh] OR "Home Care Services"[ot] OR "Home Care Services"[tiab] OR 
"Home Care Service"[ot] OR "Palliative Care"[Mesh] OR "Palliative"[tiab] OR "Palliative"[ot] OR 
"supportive care"[tiab] OR "supportive care"[ot] OR "home hospice"[ot] OR "home hospice"[tiab] OR 





('pharmacist'/exp OR 'pharmacist*’ OR 'hospital pharmacy'/exp OR 'hospital pharmac*’ OR 'pharmacist 
intervention'/exp)  
AND  
('analgesia'/exp OR 'analgesi*' OR 'pain management index'/exp OR 'pain'/exp OR 'pain*' OR 'palliative 
nursing'/exp OR 'palliative nursing')  
AND  
('hospice care'/exp OR 'hospice care' OR 'hospice'/exp OR 'hospice*' OR 'palliative therapy'/exp OR 
'palliative therapy' OR 'terminal care'/exp OR 'terminal care' OR 'respite care'/exp OR 'respite care' OR 
'home care'/exp OR 'home care' OR 'supportive care'/exp OR 'supportive care' OR 'bereavement 




(INDEXTERMS(Pharmacist*) OR TITLE-ABS-KEY(Pharmacist*) OR INDEXTERMS(“Pharmacy 
Service, Hospital”) OR INDEXTERMS(“hospital pharmacy”) OR INDEXTERMS (“pharmacist 
interventions”) OR TITLE-ABS-KEY(“Pharmacy Service”) OR TITLE-ABS-KEY(“Pharmacist 
service”))  
AND  
(INDEXTERMS(“Pain”) OR TITLE-ABS-KEY(“Pain”) OR INDEXTERMS(“Pain Management”) OR 
TITLE-ABS-KEY(“Pain Management”) OR INDEXTERMS(“Hospice and palliative Care Nursing”) 
OR INDEXTERMS(“Analgesics”) OR TITLE-ABS-KEY(Analgesic*) OR INDEXTERMS(analgesia) 
OR INDEXTERMS(“pain management index”) OR INDEXTERMS(“palliative nursing”))  
AND  
(INDEXTERMS (“Home Care Services”) OR INDEXTERMS(“bereavement care”) OR 
INDEXTERMS(“Hospice Care”) OR INDEXTERMS(“Hospices”) OR INDEXTERMS(“Palliative 
Care”) OR INDEXTERMS(“palliative therapy”) OR INDEXTERMS(“Respite Care”) OR 
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INDEXTERMS(“supportive care”) OR INDEXTERMS(“terminal care”) OR TITLE-ABS-KEY 
(“Bereavement care”) OR TITLE-ABS-KEY (“home hospice”) OR TITLE-ABS-KEY (“Hospices”) OR 
TITLE-ABS-KEY(“Home Care Services”) OR  TITLE-ABS-KEY(“Palliative Care”) OR TITLE-ABS-
KEY(“Respite Care”) OR TITLE-ABS-KEY(“supportive care”)) 
 
IV. Inclusion/exclusion criteria 
 
All studies published in English between January 2010 to January 2019 were evaluated in the systematic 
review. Included articles described studies that evaluated the treatment for pain (chronic, cancer, 
neuralgia, visceral etc.) in the hospice and/or palliative care setting (e.g. routine home, continuous home, 
general inpatient, respite care). Furthermore, the studies were required to detail the pharmacist role in 
hospice/palliative care pain management, either alone or as a part of a multidisciplinary team. Finally, the 
study was required to report some form of measurable outcome, either from a clinical or cost perspective, 
such as recommendations, modifications to medication dosage, reduction in adverse events, value of 
pharmacist, etc. Articles focused on pediatric hospice/palliative care were excluded from the study, and 
medical conditions other than pain for which outcomes were evaluated were not discussed.  
 
V. Data extraction  
 
The compiled included citations were imported in a reference manager, EndNote X8 (Clarivate Analytics; 
Philadelphia, PA). There were total 702 articles which were scanned for duplicates. A total of 515 articles 
remained after removal of the duplicates, carried forward for title/abstract screening and full text review 
in a systematic review manager, Covidence (Melbourne, Australia). The full text for the articles was 
searched and downloaded online; in case of non-availability, they were requested through the Duquesne 
University interlibrary loan service. One reviewer was involved in assessing the eligibility of the articles 
throughout the systematic review. In case of any ambiguity, it was resolved through discussion between 
thesis advisor and the reviewer.  
 








































Further definitions of reasons for exclusion: (1) pharmacist role not specified: study did not include pharmacist 
involvement in pain management, (2) outcomes differ from the review: study did not detail measurable 
clinical/economic outcomes, (3) non-research studies: descriptive analysis only without research intervention, (4) not 
found: full texts were not available via online/inter-library loan, (5) duplicates: articles previously failed to be excluded 
in duplicate removal procedure, (6) reports: official announcements        
Records identified through searching PubMed, 
Embase and Scopus  
























Records after duplicates removed 
(n = 515) 
Records excluded 
(n = 346) 
Full-text articles assessed 
for eligibility 
(n = 169) 
Full-text articles excluded (n = 156) 
 41 pharmacist role not specified 
 36 outcomes differ from review aim 
 25 abstracts from symposium/conferences 
 13 non-research studies 
 11 non-hospice setting 
 10 not found 
 6 non-pain-oriented intervention 
 4 non-English 
 4 duplicates 
 3 results not mentioned in the article 
 2 reports 
 1 pediatric sample 
Studies included in 
qualitative synthesis 
(n = 13) 
Records screened 
(n = 515) 
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VI. Results  
 
A total of 169 full texts were scanned for inclusion, with Figure 1 describing the reasons for exclusion. 
Finally, a total of 13 articles were finalized for qualitative synthesis. Of all these articles, six were 
conducted in the US,51,52,55-58 two in Japan59,60 and other countries (one each in China,61 Poland,62 UK,63 
Qatar,64 and Korea65). 
 
VII. Extraction  
 
Table 1 gives an overview of included studies, regarding the setting, pharmacist role, outcomes 
assessment, study sample, key findings, and limitations. Out of the 13 studies, seven (54%) prospectively 
evaluated the impact of a clinical pharmacist on patient pain control. Four studies (31%) retrospectively 
evaluated a pharmacist-led intervention in hospice and palliative care and two studies (15%) conducted 
survey research among pharmacist/hospital staff to understand pharmacist’s contribution to hospice and 


























outcomes; Evaluate the 
impact on length of stay 
(LOS), length from 
admission to palliative 
care consult (LTC), and 
time from consult to 
discharge and death 
(CTD). 
Retrospective study of 
patients under part-
time palliative care 
clinical pharmacist 
care as part of a 
consultation team 
Hospitalized patients 
seen by pharmacist 
September 1, 2015, 
and March 30, 2017. 
(1) guiding the transdisciplinary 
team on medication selection, 
dosing adjustments and titrations, 
(2) educating on medications, 
importance of adherence, 
symptoms,  (3) recommending 
changes to medication orders, labs, 
and diagnostic testing, (4) serving 
as liaison between the palliative 
care team and the department of 
pharmacy, (5) providing home 
medication supply at discharge, 
and (6) follow up communication 
with the outpatient palliative care 
team. 
Pharmacist involvement resulted in a significant 
difference in pain consultation and days from 
consult to discharge VS to the patients seen by 
the palliative are team. In total, patients received 
an average of 3.5 interventions and 4.1 
documented outcomes. Most common 
interventions and outcomes: optimized symptom 
drug regimen (92.75%), education of 
patient/provider (90%) and change in med 
therapy implemented (90%), healthcare 
professionals educated (84.5%). There was a 
significant difference between patients seen by 
pharmacist VS palliative team for: consultation 
of pain (80.9% vs 39.4%, p<0.005).  
Comparison based on pharmacist visit time 
within 3 days of hospitalization VS 3 or more 
days after hospitalization: LOS (10 VS 25, 
p<0.005), LTC (3.79 VS 9.48, p<0.05), and 








effectiveness of opioid 
treatment between 
cancer patients receiving 
interventions from 
Clinical Pharmacist Led 
Guidance team (CPGTs) 






18 years or older, 
diagnosed with cancer 
pain by an oncologist, 
and able to receive 
opioid treatment for 
more than two weeks. 
Patients previously 
treated with opioids 
were also included 
(1) physician and patient 
education, drug-use monitoring,  
evaluation of drug responses, (2) 
consultation in cases of pain or in 
case of complications (without 
prescribing ), (3) monitoring drug 
efficacy and toxicity (follow-up) 
Outcomes for standardization of opioid 
administration broadly improved through the use 
of the CPGT intervention, including more 
frequent pain assessments before therapy 
(OR:3.39 [2.78-4.14]), dose titrations before SR 
formulations (OR: 8.12 [6.34-10.78]) and 
dosage increases (OR: 9.67 [8.11-11.02]). Fewer 
inappropriate prescriptions and conversions 
were utilized, while SR formulation use 
increased. CPGT resulted in better pain control 
(scale 1-10) by site (bone [3.1 vs. 4.2, P=0.038], 
body [1.2 vs. 3.6, P=0.041], visceral [1.9 vs. 3.1, 
P=0.024), nerve [2.7 vs. 4.8, P=0.045]) and 
improved QOL (48.3 vs. 37.6, P=0.032, scale 0-
60). Adverse events were significantly reduced 







for patients with 
advanced cancer pain are 
feasible and acceptable. 
Prospective, 
multicenter study. 
Patients with cancer 
received consultation 
regarding  medication 
use from the 
pharmacist along with 




advanced cancer pain 
between November 
2015 and March 2017 
aged 16 years or 
older, aware of their 
diagnosis, on a 
prescribed opioid, not 
on any anticipatory 
medicines for end-of-
life care and with 
capacity to provide 
informed consent and 
complete 
questionnaires. 
Provide medicine consultation and 
recommendations to the patients, 
identify drug-related problems, 
and provide intervention   
A mean of 2.5 drug-related problems per patient 
were identified, most commonly including 
effects of drug not optimal (n=25) and unclear 
problem/complaints (n=7). Lack of information 
(n=15) and non-adherence (n=16) were the main 
causes reported. Intervention provided for most 
of DRPs and their causes was patient 
counselling (n=35). The intervention has a 
positive impact on the mean pain score pre vs 







Evaluate the impact on 
pain management by 
multidisciplinary 
palliative care team 
(mPCT) and the team 
pharmacist. 
Retrospective analysis 
of the medical chart 
review. Patient 
reported pain intensity 
was recorded three 
times: (1) seven days 
before palliative care 
unit (PCU) admission 
(day -7), (2) on the 
day of admission (day 
0), and (3) seven days 
after admission (day 
7) 
18 years or older, 
hospitalized for 7+ 
days between April 
2014 and December 
2015, after being 
transferred from the 
wards, emergency 
center, or outpatient 
clinics due to 
worsening of 
oncologic pain. 
(1) recommending medications 
and evaluating analgesics, (2) 
validation and intervention of 
analgesic prescriptions based on 
the type and severity of pain, dose, 
routes, and schedule, (3) 
assessment of contraindications, 
drug interactions, and adverse 
effects, (4) patient counseling for 
nonadherent patients, (5) 
educating staff on evidence-based 
treatment with new analgesics 
Mean pain intensity and appropriate use of 
analgesic improved gradually for patients 
admitted in the PCU with the mPCT. 
Appropriate analgesic use was higher when 
compared to patients who were taken care by 
mPCT (35.04% on day -7, 34.19% on day 0 and 
75.21% on day 7) (P<0.001). Appropriate opioid 
use was  76.9% on day 7, 35.9% on day 0 and 
35.9 on day -7 (P<0.001) and mean pain 
intensity score was 2.66 on day 7 of PCU and 
4.05, 3.16 on day 0 and day -7, respectively. 
Decrease in inappropriate use of opioid was 
observed on PCU admissions. As per the Korean 
Cancer pain management guidelines, 
appropriateness of analgesic doses (for chronic 
pain: 87.2%, 80.3%, and 95.7% on day 7, day 0, 
and day 7, respectively; P= 003; for 
breakthrough pain: 88.9%, 88.9%, and 96.6% on 
day 7, day 0, and day 7, respectively; P=0.049) 
and the rate of reassessment of each patient’s 
pain to adjust the medication for breakthrough 
pain (63.2%, 68.4%, 91.5% on day 7, day 0, day 








Examine the clinical, 
educational and research 
activities of pharmacist 
in a palliative care team, 
their perceived 
contribution to the team 





mailed to pharmacists 
in cancer hospitals 
across the country 
Pharmacists working 
in the palliative care 
for cancer patients 
from November 2012 
to January 2013. 
(1) ward rounds, counselling 
patients, managing adverse drug 
effects, drug interactions, 
strategies for titration and rotation 
of drugs, provided 
information/suggestions about the 
efficacy, adverse effects, and 
interactions of drugs used to 
alleviate symptoms, informed the 
primary pharmacists about patient 
pharmacotherapy requests, (2) 
education and research activity of 
palliative care: organizing 
conferences, presenting research 
work.  
Clinical activity provided by pharmacist were 
direct counselling of the patients regarding 
opioids (29%) and adverse effects due to opioids 
(19%). As a part of the palliative care team they 
provided suggestions to the team regarding 
managing adverse effects of opioids (35%), 
rotation of opioids (34%), pharmacology of 
opioids (34%), drug interaction of opioids (33%) 
and managing adverse effects of opioids (21%), 
pharmaceutical production of opioids (21%). 
Pharmacist are most commonly involved in 
providing suggestion to team’s primary 
pharmacist sometimes (35%) and often/always 
(24%), 70% pharmacist agreed on some level of 
contribution to the palliative care team, 16% 
reported they could not contribute and main 
perceived reasons for no contribution were 





interventions and patient 
outcomes of a 
pharmacist-led 




of medical records 
conducted at cancer 
center with a 
transdisciplinary 
clinic with two 
pharmacists. 
18 years or older, with 
a diagnosis of cancer 
between March 2011-
2012.   
(1) assess, initiate, stop, and or 
adjust therapy for the management 
of pain, nausea/vomiting, under 
physician direction, (2) optimize 
medication therapy, (3) compose 
clinical encounter and documented 
recommendations for therapy in 
the electronic medical record, (4) 
schedule follow-up visits to 
monitor symptoms and medication 
use. 
Patients with severe pain (48%) showed gradual 
decrease in pain over the four visits. More 
patients (64%) were found in the stable pain 
state by the end of the four visits. Pain 
medication problems identified by the 
pharmacist included lack of efficacy, nausea, 
vomiting decreased with increase number of 
patient visits to the setting. Majority of patients 
(61%) were assigned a change in the opioid 













multicenter study of 
pharmacist 
assessments as part of 
the clinic regarding 
drug interaction, 
duplication in therapy, 
lack of efficacy and 
untreated condition.  
Oncology patients 
referred to the clinic 
for early palliative 





Prior to visit: evaluation of 
medication list; check for drug 
interaction; assess for duplication 
therapy; form a patient-friendly 
medication list 
 
On the day of visit: reviewing 
patient's medication containers; 
assess for drug interaction, adverse 
effects, adverse effects and 
untreated conditions; provide 
recommendations and consultation 
service 
 
After visit: provides 
recommendations to  team 
regarding medication changes, 
provides updated medication list , 
fill out the assessment, providing 
consultation 
The results of the assessment were reported as 
follows: (1) Access to medication: higher cost 
(53.5%), transportation issues (20%), lack 
healthcare access (32%), (2) adherence to 
medication: missing at least one dose (62.7%), 
(3) medication therapy review: most common 
problems were duplication of therapy (46.7%) 
for breakthrough of sleep (25.6%) and pain 
(20.5%), drug interaction (44%) with the 
majority due to warfarin (24.3%) and 
metoclopramide (21.6%), side effects (74.7%) 
with most common being constipation (27.9%), 
lack of efficiency of drugs (94.7%) mostly the 
drug used for pain (31.9%), and untreated 
conditions (73.3%) such as fatigue (25.5%) and 
constipation (12.7%). Positive feedback was 
acquired from the patient for involvement of a 









and validate the 
pharmacist’s role on a 
transdisciplinary 




of medical records 
related to patient 
interactions with a 
palliative care 
pharmacist. 
Patients who had a 
palliative care consult 
order and a 
pharmacist-generated 
clinical note in the 
medical record 
between November 1, 
2013 and October 31, 
2014. 
(1) participate in palliative care 
team rounds three times each 
week; (2) contribute to 
management plan for all patients 
with symptom  issues; (3) 
providing medication education to 
patients, families, and staff; (4) 
coordinating interventions for 
pharmacy-related issues with 
discharge planners and physicians; 
(5) participating in family 
meetings with physicians and 
other palliative care team 
members; (6) initiate and adjust 
opioid doses, including transitions 
from parenteral to oral agents, and 
participate in pain and dyspnea 
management for end of life care 
patients. 
Pharmacist intervention resulted in reduction 
(4.6 to 2.0) of pain score in acute and chronic 
pain suffers (5.7 to 2.5 points). Patients with 
interventions for moderate to severe signs of 
symptoms showed improvement in their 
condition; nausea 42/44 (95.4%), dyspnea 82/92 
(89%) and anxiety 39/45 (86%), Pharmacist 
participated in family meeting (n=142), 
completed a total of 58 advance care directories 
and  forms. A considerable cost saving was 
observed through direct cost reduction of 
$100,000 due to treatment discontinuation 







To provide an overview 
of the current state of 








directors and hospice 
physicians. 
Pharmacists, hospice 
directors and hospice 
physicians at 93 
residential hospices 
identified through a 
web database in 2012. 
(1) the most common service 
provided by the pharmacists was 
providing advices on drugs and 
medical devices (75%) followed 
by various other responsibilities 
such as  dispensing of drugs and 
medical devices, co-participation 
in therapy management, 
participating in rationalizing of 
drug therapy and monitoring 
adverse reactions, (2) as per the 
hospice directors expected role of 
pharmacist was participation in 
clinical trials and training hospice 
care staff, preparing sterile drug 
formulations,  preparing enteral 
feeding solutions and 
compounding drugs, (3) other 
roles such as advise members of 
the therapeutic team, providing 
opinions to physicians, advise on 
pharmacotherapy choices. 
Ten (63%) pharmacists estimated their 
involvement in this service at a level of 100%. 
The hospice directors and physicians indicated 
the necessity for including the pharmacist within 
the therapeutic team more frequently than 
respondents employed at hospices where there 
was no pharmacist contribution (p=0.02480 and 
0.003, respectively). There was no statistically 
significant difference between the opinions of in 
the three groups of respondents regarding the 
benefits associated with providing 
pharmaceutical services at a hospice except for 
better selection of drugs for individual patients 
was indicated more often by hospice 
pharmacists than hospice directors (p=0.03) and 
physicians (p=0.02). Majority of the opinions 
regarding benefits employing pharmacist in 
hospice care were improved access, decrease 








Investigate clinical and 
financial impacts of 
adding a clinical 
pharmacist to the 
hospice care team 
Prospective, single-
center study. A 
clinical pharmacist 
was added to the 
interdisciplinary 
group (IDG) 
Hospice care patients, 
comparing 2016 (pre) 
and 2017 (post) data 
(1) attend IDG meetings, (2) 
formulary management and 
adherence for hospice patients, (3) 
chair for the P&T committee, (4) 
prevention of controlled substance 
diversion, (5) education of clinical 
staff, (6) general drug reference 
for physicians and nurses, (7) 
consultation, (8) present emerging 
trends in drug therapy for hospice 
patients. 
Financial impact: As per the time spent in the 
IDG meeting and its preparation, value of 
pharmacist was about $138 per hour. Average 
PPD drug cost decreased from $5.44 to $4.07, 
resulting in direct drug cost saving of $329,797 
from baseline and cost benefit per intervention 
per month of $72.52. Total cost saving was  
$427,705 including indirect cost saving 
($15,750) and outside consultant pharmacist 
($60,000). 
 
Clinical impact: Major impacts in reducing 
unnecessary medications on the patient's 
medication list, improving medication use 
during drug shortages and eliminating medicine 






method of care delivery 
begun at the University 
of North Carolina; 
describe the 
characteristics of the 
population seen and the 
role of the individual 
members of the 
interdisciplinary team, 
and provide an early 
analysis of the program’s 




medical chart review 
for studying the 
impact of a 
pharmacist led multi-
disciplinary team for 
supportive care in 
cancer patients 





Clinical pharmacist practitioner 
approved to provide drug therapy 
management under physician 
direction. Two delivery models: 
(1) consult service, with care 
provided at clinic where patient 
already seen, and (2) structured 
visits at separate clinic with initial 
assessment (cognitive/medication) 
by pharmacist. Encounters studied 
included consultation by 
nurse/pharmacist (28.6%) or 
nurse/pharmacist/physician 
(22.7%); 10.3% included 
pharmacist consultation alone 
Across first 18 months of service, patient 
volume and encounters increased from 4.5 to 6.6 
per month, and 13 to 20 per month, respectively. 
Among a subset of 54 patients assessed on pain 
medication, encounters with the service resulted 
in 40% of patients receiving an increased dose, 
23% receiving a new medication, 15% switched 
to another opioid, and 15% with no change; 
methadone was the most common 
addition/switch. Among a subset of 49 patients 
assessed, reductions in symptom scores for pain, 
nausea and constipation decreased and 







Create a baseline 
inventory of clinical 
pharmacy interventions 
after establishment of an 
academic cross-
appointment in palliative 
care and to assess the 




study. Data collected 
included: (1) number 
of patients admitted to 
palliative care while 
study pharmacists 
were on service, (2) 
actual or potential 
drug therapy problem, 




therapy problem, and 
(4) acceptance by the 
prescriber, if 
applicable. Responses 
of an online survey 
from the pharmacist in 
Qatar and Canada 
were compared for 
assessing importance 
of each type of 
recommendation.  
Palliative care service 
between September 1, 
2013 and December 1, 
2013.  
 
Additional data was 
also collected via 
pharmacist survey. 
(1) identifying actual or potential 
drug therapy problem (2) 
assignment of an 
intervention/recommendation for 
the identified problem (3) ranking 
of the perceived importance of 
each of the recommendation given 
by study pharmacists  
32 patients were seen (the average intervention 
rate of 3.0 per intervention per patient ). On 
removal of education-related interventions, 81% 
of pharmacist's recommendations were accepted 
by  physicians. Discontinuation of drug therapy 
(29%) and initiation of drug therapy (25%) 
recommendations were most common while 
referral to other professionals (2%) was least 
common. A significant difference existed 
between overall rankings for each question 
between pharmacists in Canada and Qatar 
(p<0.05). Initiation of drug therapy (10) 
(p=0.955), discounting of drug therapy (10) 
(p=0.758) and, physician/nurse education (10) 
(p=0.918) were among highly rated 
interventions/recommendations among the 







Evaluate the effect of 
continuous interventions 
for pain management 
and opioid-induced side 






from the first visit for 
opioid introduction to 
interventions via 
telephone to assess 
pain patterns, doses, 
side effects, and 
recommendation 
acceptance rates.  
Outpatients 
administered opioid 
treatments for cancer 
pain relief and who 
received pharmacist 
interventions from 
October 2014 to 
March 2016. 
(1) introduction to opioids at the 
first visit, (2) interventions through 
telephonic interviews between 3-7 
days of first visit, (3) daily patient 
counseling, (4) training patient to 
assess pain intensity and pain 
response to analgesics, how to 
treat breakthrough pain using 
rescue doses, and how to prevent 
or treat side effects caused by 
analgesics, (5) increasing opioid 
doses or administering alternative 
opioids was recommended to the 
physicians in case of need for 
titration of analgesic preparation 
for pain control, (6) recommended 
adequate antiemetic or laxative 
drugs for symptom management 
Pain intensity decreased gradually along with 
increase of visits (occasion) with the 
pharmacists. A significant change in the worst, 
average, and least pain scores at visits 2 and 3 
compared with those at occasion 1 (p<0.001). 
Side effects scores showed a significant 
difference only between visit 1 and 3 (n=18, 
p=0.030). Pharmacist provided 48 new 
recommendations with an acceptance rate of 
85.4%; maximum accepted (21/25) 
recommendations were change of dose (n=25) 
out of which (n=20) there were dose changes for 
opioids. 
 
CPGT- clinical pharmacist-led guidance team, CTD- time from consult to discharge and death, DRPs- drug related problems, IDG- interdisciplinary group, LOS- length of stay, LTC-
length from admission to palliative care consult, mPCT- multidisciplinary palliative care team, NCCN- National Comprehensive Cancer Network guideline, OR- odds ratio, PCU- palliative 
care unit, PPD- per patient day, QOL- quality of life, SR- sustained release.
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a. Prospective evaluations of pharmacist-led interventions 
 
These seven identified studies contain an intervention led by a pharmacist or detail a pharmacist 
involved in the hospice and/or palliative care of patients. Outcomes of administered 
interventions were assessed by evaluating pain intensity. Six out of the seven studies focused 
on the management of pain among patients with cancer in a hospital/clinic setting51,52,55,61,63,64  
and one study was conducted in an outpatient setting.59 
 
A study by Chen et al61 compared the effectiveness of opioid treatment between patients with 
cancer receiving care from a clinical pharmacist-led guidance team (CPGT) and a control 
group. One of the important pharmacist roles within the CPGT was evaluation of pain and 
follow-up with patients. Pharmacists were involved in selecting drug therapy for patients along 
with physicians. The procedures included in selection of drug therapy were initial pain 
assessment, dose conversion, selection and titration, all of which were referred to as process 
parameters. Similarly, outcome parameters contained results of  pain evaluation before and 
after medication administration, occurrence of adverse events and quality of life measurements. 
Pharmacists collaborated with nurses in following up regarding management of adverse 
effects. The effect of a clinical pharmacist in the CPGT group was assessed for both the process 
and outcome parameters. Results from the study show that there was a higher rate of accurate 
assessment of pain severity in the CPGT group (97.4% vs 71.8%, p<0.001). Process parameters 
such as standardized dose titration, changes in specific opioids and errors in dose conversion 
improved significantly in the CPGT group vs control group (p<0.001). The pain scores 
assessed using a numerical/visual scale for the CPGT group demonstrated better control for 
bone pain (3.1 vs. 4.2, p=0.038), body pain (1.2 vs. 3.6, p=0.041), visceral pain (1.9 vs. 3.1, 
p=0.024), and nerve pain (2.7 vs. 4.8, p=0.045). The rates of adverse events among the patients 
in the CPGT intervention group were lower than the control group, with a significant difference 
in rates of constipation, nausea, and vomiting (p=0.041, 0.028, 0.035). Further, quality of life 
(QOL; on a scale from 0-60) scores in the CPGT group were found to be better compared to 
the control group (48.3 vs 37.6, p=0.032). 
 
Mancini55 evaluated the value of adding a part-time pharmacist for the palliative care of 
patients with cancer. The service provided by the pharmacist was distributed among pre-visit, 
visit and follow-up services. Before the visit, the pharmacist evaluated the medication list of 
the patients from the electronic medical records and checked for drug interactions and 
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duplications of therapy. During the visit, in coordination with the nurse, the pharmacist went 
through the medication list and discussed any difficulties with adherence, making 
recommendations when necessary. After the visit, the pharmacist guided the team regarding 
changes in drug therapy for the patient, if applicable, and filled out the assessment. The 
pharmacists under nurse practitioner’s guidance made necessary medication recommendations. 
The assessment evaluated five areas of medication management, including: (1) medication 
adherence, (2) access to medication, (3) continuity of care, (4) medication reconciliation, and 
(5) education.  Patients reported various concerns regarding access including cost issues (n=40, 
53.5%), transportation costs (n=15, 20%), and access to healthcare (n=24, 34%). The 
medication therapy review of the patients allowed the pharmacists to go through drug 
interactions, adverse effects, lack of drug efficacy and untreated conditions. The results showed 
most common duplication therapies included sleeping meds (n=9, 25.6%) and breakthrough 
pain meds (n=4, 26.5%), side effects included constipation (n=16, 27.9%), and lack of efficacy 
in controlling pain (n=23, 31.9%). The most common untreated condition found during the 
assessment was fatigue (n=14, 25.5%).  
 
Valgus et al52 evaluated the integration of a pharmacist in ambulatory care for an oncology 
supportive service on a team with a nurse and a physician. Typically, a structured visit was 
arranged for patients on acquiring approval from the primary oncologist. An initial cognitive 
assessment and detailed medication history review was conducted by the pharmacist, and then 
physicians and nurses went through a detailed symptoms management assessment. Finally, a 
team meeting was held for discussing treatment recommendations, medication changes, 
symptoms interventions or any referral services to be provided to the patient. The collected 
data included demographics, symptoms scores (scored on a scale from 1=no pain to 5=most 
severe) and medication for symptoms (pain, nausea, vomiting and constipation). Based on 
referral encounter data from a total of 292 patients, 30 (10.3%) patients were consulted alone 
by the pharmacist, and in 99 (34%) encounters, the pharmacist worked as a team with 
physician/nurse. Out of total 89 patients, 88 (75%) visited the outpatient service for pain 
management. Out of total 54 patients with pain, 52 (96.29%) were taking either methadone or 
another long-acting opioid. After the initial visit, it was found that 40% of the patients had 
increases in their medication doses, 23% had a new medication added, and 15% switched to 
other opioids or had methadone started as a new therapy. The initial analysis of records of first 
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49 patients showed an improvement in the mean symptoms scores of pain management across 
the three visits evaluated, although this was not statistically evaluated. 
 
Richter51 studied the clinical and financial impacts of adding a clinical pharmacist in the 
hospice care interdisciplinary group (IDG). The clinical pharmacist carried out functions such 
as preventing controlled substance diversion, attending IDG meetings, educating other clinical 
staff, consulting pharmacist of the care centers, promoting formulary management and 
adherence. The financial benefits showed a decrease in per patient drug (PPD) cost from 2016 
to 2017 from $5.44 to $4.07 and a direct drug cost savings from the interventions made in the 
IDG meeting of $329,729. The month-to-month intervention cost saving was estimated at 
$75.52. Interventions not made during the IDG meeting demonstrated savings of 
approximately $22,189. Overall, there was decrease in number of emergency visits and patient 
falls. Overall, including a clinical pharmacist in the hospice care team benefited by saving 
$427,705 annually. In terms of clinical functions, the clinical pharmacist was involved in 
patient consultation and accompanying physicians or nurses during patient visits. This assisted 
in patient education regarding medication use, exploring alternative medication options in case 
of lack of access to drugs and reducing use of unnecessary medications. The major clinical and 
financial impact of the clinical pharmacist was through their involvement in optimizing therapy 
regimens for patients and formulary management. The pharmacists consulted patients on topics 
such as drug dosing and selection strategies in a variety of settings from inpatient care centers 
to the patient’s home. Overall, there was a positive impact of adding the pharmacist to the 
clinical team as formulary adherence and accuracy was observed in the medical lists of the 
patients.  
 
Yamada et al59 explored a pharmacist-led intervention for pain management among patients 
with cancer within an outpatient clinic setting. The intervention was provided before the 
physician visit and during every follow-up visit. The service involved patient counseling 
through face-to-face interviews and telephone. During the session, patients were taught how to 
assess pain intensity and response to analgesics, how to treat breakthrough pain using rescue 
doses, and how to prevent or treat side effects caused by analgesics. A gradual decrease of the 
proportion of patients reporting severe pain after pharmacist intervention occurred across 
visits: 15/26 (51.7%), 10/27 (37.0%), 7/24 (29.2%), 4/14 (28.6%), 1/5 (20.0%), and 1/5 
(20.0%), on visits one to six, respectively. Apart from this, the pharmacist also made 
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recommendations regarding change of dose, introduction of new medications and termination 
of existing medication if necessary. Out of 48 total recommendations made, 41 (85.4%) were 
accepted by the physicians.  
 
Edward et al63 evaluated the feasibility and acceptability of pharmacist-delivered medicine 
consultation for patients with cancer. Community pharmacists were directly accessible by the 
patients in case of emergency or untreatable conditions, and the study quantified drug-related 
problems and the recommendations provided by the pharmacists. The pharmacists carried out 
telephonic or face-to-face medication utilization reviews (MUR), followed by patient and 
pharmacist feedback regarding change in intensity of pain before and after the consultation (on 
a scale of 0=no pain to 10=pain as bad as they could imagine). In total, 47 drug-related 
problems were identified in 17 patients with a mean of 2.5 per patient. The problems were 
classified based on Pharmaceutical Care Network Europe Foundation (PCNE) classification. 
The most common drug-related problem encountered during the consultation was pain due to 
reasons such as no effect of drug treatment (P1.1) (n=1, 7%), effect of drug treatment not 
optimal (P1.2) (n=12, 80%) or result of untreated symptoms (P1.3) (n=3, 13%). The most 
common cause was lack of information regarding side effects of the drug (C7.1) (n=6/15, 40%) 
and advice (C5.2) (n=8/16, 50%). The most common intervention provided for the common 
drug related problems was patient counseling for pain (I2.1) (n=12/35, 34%). The post-
consultation pain score was found to be improved over that of the pre-consultation pain score 
(mean: 3.45 vs 3.95, p-value not specified). The telephonic consultation found to be highly 
acceptable amongst the patients and healthcare professionals.  
 
Wilby et al64 described the modernization that took place in the palliative care setting in Qatar 
as a part of National Care Strategy. Clinical pharmacists were added as a core component of 
the palliative care multidisciplinary team. The pharmacist underwent academic cross-
appointment training which was accredited by Canadian Council of Accreditation of Pharmacy 
Programs (CAPP). Along with enrollment in a clinical program, they worked in a palliative 
care setting. An inventory list of recommendations was made based on consultation provided 
by these cross-appointed pharmacists. The perceived importance of these recommendations 
was ranked by both the pharmacists in Canada and Qatar (on a scale of 1=lowest importance 
to 10=highest importance). The recommendations list most frequently identified  
discontinuation of drug therapy (29%) and initiation of drug therapy (25%). There was no 
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significant difference found between overall rankings for each question between pharmacists 
in Canada and Qatar (p>0.05). The perceived importance of the interventions between the 
pharmacist at Qatar and Canada was as follows: initiation of drug therapy (10, p=0.955), 
discounting of drug therapy (10, p=0.758) and, physician/nurse education (10, p=0.918). The 
study provides a strong rationale of adding a clinical pharmacist in a palliative care setting as 
an evidence of the services they can offer.  
 
b. Retrospective evaluations of pharmacist impact 
 
Atayee et al56 described the outcomes associated with adding a clinical pharmacist to a 
palliative care service in an inpatient setting. The study retrospectively assessed hospitalized 
patients evaluated by a specialist palliative pharmacist at University of California, San Diego. 
The analysis focused on identifying the inpatient pharmacist interventions provided to the 
patients, as well as evaluating the outcomes related to the interventions provided as a part of 
the primary assessment. The study also evaluated length of hospital stay (LOS), reason for 
consult to palliative care team, length from admission to palliative care consult (LTC), and 
time from consult to discharge or death (CTD) of the patients. In the inpatient setting, 
pharmacists were involved in educating/training other team members and patient family 
members, dose changing, and medication selection. Pharmacists served as liaisons between the 
palliative care team and the department of pharmacy at the medical center. The most common 
documented intervention and outcome found were optimizing palliative care medications 
(n=371, 92.75%) and change in the medical therapy implemented (n=300, 90%). Early 
exposure of clinical pharmacists to the patients (i.e. within >3 days of hospitalization) was 
found to improve LOS, LTC and CTD (10, 3.79 and 6.09)  compared to exposure after >3 days 
of hospitalization wherein LOS, LTD and CTD was 24 (p=0.00004) , 9.48 (p=0.013) and 14.59 
(p=0.000009).  
 
Naidu57 assessed the role of a palliative care pharmacist in a community hospital. Pharmacist 
responsibilities include participating in team rounds, forming symptom management plans, 
educating staff and family members, coordinating pharmacy related interventions, and 
completing Physician Orders for Life Sustaining Treatment (POLST) forms. Alongside 
physicians, pharmacists were able to initiate, adjust or transition medications as per patient 
pain relief requirements. A retrospective cohort study was conducted and evaluated medical 
records of patients who had palliative consult orders and a clinical note from a pharmacist in 
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their clinical record. The data included patient’s pain scores (on scale of 1 to 10) before and 
after 24 hours, of  intervention administered. A reduction in pain score from 4.6 to 2.0 points 
was seen among acute pain patients (n=125, 47%) and 5.7 to 2.5 in chronic pain (n=140, 57%) 
patients after administration of pharmacist intervention. Out of the total patients who stated a 
numerical pain value (n=191), 174 (91%) met their pain goal within 24 hours. In case of 
symptom management, nausea and anxiety scores were improved post-intervention. The most 
common interventions provided by the pharmacist were education, counseling patients and 
making proper medications available for them. The pharmacist service had a positive financial 
impact due to discontinuation of unnecessary medications, tests, or procedures. Palliative 
pharmacists achieved a direct cost reduction of $1000 due to treatment discontinuation. In line 
with published literature, a reduction in cost per day of $279 for patients discharged alive and 
$374 for patients who died as inpatients was achieved through the consultation program.  
 
Ma et al58 described the role of pharmacist on a palliative care team in an outpatient setting, 
providing consultation during visits for pain management and involved in documentation and 
interventions on medication problems. Advanced care planning was provided to assess, initiate, 
stop, and/or adjust therapy for the management of pain, nausea/vomiting, and other symptoms 
due to lack of efficacy, adverse effects, nonadherence or missed doses, drug interactions, 
evaluating duplications in therapy and providing recommendations regarding medications. All 
patients assessed by the palliative care pharmacists were included in the study, with their pain 
(on a scale of 1-10) scored as mild (1-3), moderate (4-5) or severe (6-10). During the first visit 
(n=80), 38 (48%) were classified with severe pain, and at the second visit (n=59), 21 (36%) 
reported improvement in pain. At third (n=43) and fourth visits (n=33), the number of patients 
with stable pain were consistent (21 [49%] and 14 [42%]). All the pharmacists identified 
constipation as an adverse effect in the subsequent visit and the most common intervention 
provided was starting a new medication.  
 
Geum et al65 explored the impact of a multidisciplinary palliative care team (mPCT) and 
pharmacist on pain management. Data from medical records of the patients admitted in the 
palliative care unit (PCU) was retrospectively collected. The mPCT team, along with the 
pharmacist, conducted medical rounds collecting information regarding pain severity and other 
symptoms. The pain intensity (scored on a scale of 0 to 10) was documented seven days before 
PCU admission (day -7), on the PCU admission day (day 0), and seven days after the PCU 
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admission (day 7). Pharmacists were involved in providing medical therapy recommendations 
and evaluating use of analgesics. The analgesic use followed the Korean Cancer Pain 
Management Guidelines and the National Comprehensive Cancer Network (NCCN) 
guidelines. A medication was deemed eligible for use if it satisfied all six categories of 
recommendations within the guideline, including: (1) drug selection based on the type and 
severity of the pain, (2) dosage for chronic pain, (3) for breakthrough pain, (4) reassessing each 
patient’s pain to adjust the pain medication to meet the patient-specific goals for comfort, 
function, and safety, (5) analgesic use that reflects renal or hepatic function, and (6) monitoring 
adverse effects. The results of the study showed that pain scores were worst on day 0 (4.05), 
compared to day -7 (3.16) and day 7 (2.66). The appropriateness of analgesic used improved 
along the days of the admission, from day -7 (35.0%), day zero (34.2%) to day 7 (5.2%) 
(p<0.001). The analgesic use as per the six categories recommendations improved over time 
(day -7, day 0, day 7) for chronic pain (87.2%, 80.3%, and 95.7%) (p<0.003), break through 
pain (88.9%, 88.9%, and 96.6%) (p<0.049) and monitoring of the side effects (65.0%, 65.8%, 
and 86.3%). 
 
c. Survey questionnaires regarding pharmacists in hospice and palliative care 
 
Ise et al60 examined responses from palliative pharmacist surveyed regarding their 
understanding of their activities on the palliative care team. The pharmacists were asked 
questions regarding their clinical, education, and research contributions in a palliative care 
setting and their perception of their contribution to the service. Clinical activities were rated 
on a five-point Likert scale (one=rarely to five=everyday). The highlighted clinical activities 
identified from the responses were: (1) direct counseling of patients about opioid information 
(18%) and adverse events of opioids (19%), (2) provision of information to the palliative care 
staff about managing adverse events of opioids (21%) and pharmacology of opioids (20%), (3) 
attending wards (79%) and conferences (94%). Their contribution to education and research 
activities was measured through a yes/no question. Approximately 80% of pharmacists 
organized a conference in their own designated cancer hospital. The perception of pharmacist 
contributions to the palliative care team was assessed using a yes/no question and associated 
reasons were rated on five-point Likert scale (strongly agree to strongly disagree).  Out of 304 
pharmacists, (n=212) 70% of pharmacists rated their contribution to palliative care services as 
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100%. Those who did not perceive their contribution to the fullest identified a shortage of time 
(90%) and staff (68%) for their lacking contribution.  
 
Pawlowska et al62 administered a survey regarding current and future roles of clinical 
pharmacists and their collaborations with physicians in a residential hospice among three sets 
of responders: pharmacists, physicians and hospice directors. Each responder had a different 
set of questions to answer; the hospice directors and physicians were asked about their attitudes 
towards the contribution of a pharmacist in the residential hospice. Pharmacists were asked 
questions regarding the services they provided, their role in solving drug-related problems and 
making the therapy more cost-effective. The majority of the respondents supported the idea of 
including a pharmacist in the palliative hospice care team. Specific reasons for this as per the 
pharmacists were delivering cost-effective therapy, while hospice directors identified better 
drug management and decision-making regarding therapies as the reason. A need for advice 
from the pharmacist was expressed by 53% of physicians (n=16/30) on the following topics: 
new drugs, rationalization and cost of pharmacotherapy, reimbursement, generic drugs, 
availability of drugs on the pharmaceutical market, drug interactions and compounding. All 
the respondents thought that adding a pharmacist to the hospice team would be beneficial for 
proper storage of drugs (61%), decreasing cost of the therapy (57%) and improving access to 
the drugs (53%). 
 
VIII. Overall summary  
 
The breadth of studies focused on evaluating the impact of adding the clinical pharmacist on 
the hospice and palliative care team for pain management of patients. The outcomes of 
pharmacist-led interventions or pharmacist involvement in palliative care were found to be 
associated with better pain control among the patients.51,52,55,59,61,63,64 The studies in the review 
assessed the effect of  study interventions on patient’s pain via evaluating pain intensity. Most 
commonly pain intensity was recorded utilizing a numerical pain scale throughout a patient’s 
visit to the healthcare setting. Interventions played an important role in optimizing a patient’s 
therapeutic regimen, identifying, and solving adverse effects related problems. Furthermore,  
Richter51 mentioned financial benefits gained due to the roles carried out by a pharmacist in a 




The current review also provides insights regarding clinical pharmacist’s role in conducting 
counseling sessions, medical rounds and completing patient’s health assessment forms.56-58 It 
also endorses pharmacist involvement in medication changes, recommendations or 
intervention suggestions as a response to the symptoms experienced by the patients.65 Ise et 
al60 and Pawlowska et al62 highlighted how pharmacists perceive their importance in the 
hospice and palliative care through administration of surveys.  
 
The results of the systematic literature review provide rationale to the aim of the study to 
understand the extent of involvement the clinical pharmacists have in hospice and palliative 
care settings.    
 
IX. Limitations   
 
Most of the studies had data from the initial phases of service implementation, where 
adding the pharmacist to the multidisciplinary team was just initiated. Therefore, 
outcomes resulting from a well-established palliative care team are not as well detailed in 
the review. Moreover, the current review largely did not take into consideration effects of 
pharmacist involvement or pharmacist-led interventions on humanistic outcomes, such as 
quality of life and improved functioning. Regarding clinical setting limitations, articles 
based on a pharmacist’s role in hospice care multidisciplinary team were comparatively 
fewer than palliative care setting.  Furthermore, non-English studies and 
seminar/conference data without full text were not included; therefore, studies written in 












CHAPTER 3: METHODS 
 
I.  Phase I of the study  
 
a. Phase aim  
 
To identify the prevalence of clinical pharmacist recommendations for methadone upon 
admission to hospice/palliative care. Further, to assess the acceptance of the pharmacists’ 
recommendations for methadone after admission to hospice/palliative care. 
b. Overview  
 
Phase I of the study was conducted in two parts of data collection. ‘Instrument #1 - Pharmacist 
data collection tool’ identified whether a recommendation for methadone was made by the 
pharmacist based on individual indications/contraindications of patients. ‘Instrument #2 - 
Researcher data collection tool’ was utilized to follow up the patients for evaluating whether 
the physicians accepted provided recommendations. Descriptive and inferential statistical 
analysis was performed on the data collected by the tools.   
1. Rationale  
 
The involvement of a pharmacist in the hospice and palliative care has shown improvement in 
pain management and optimizing other patient clinical outcomes. A study performed by Lee 
et al. documented all recommendations made by the pharmacists and their effects on the 
patient’s clinical outcomes in a palliative care setting. Out of the 87 recommendations, 73 
(84%) were accepted by physicians. The patient’s clinical outcomes were positively influenced 
by the pharmacists’ pharmacotherapeutic recommendations.66 Another study by Wilson et al. 
demonstrates that the desired clinical outcomes were achieved when the pharmacist’s 
recommendations were accepted by the physicians.67  
 
Methadone’s utilization in hospice and palliative care settings has not been optimal.41 This has 
been the case despite the medication gaining popularity for its pain management attribute 
among the patients. The medication has been studied for use in various pain states, especially 
pertaining to patients with cancer pain. The indications of using methadone found from those 
studies were: (1) management of uncontrolled pain, (2) alternative in case of opioid 
allergy/opioid adverse effects, (3)  management of neuropathic pain, and (4) pain refractory to 
other opioids.68 Similarly, use of this treatment for pain management has various 
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contraindications. A clinical practice guideline on safe use of methadone suggests 
contraindications for using methadone including: (1) prolongation of QTc interval, (2) 
potential risk factors of QTc prolongation like electrolyte abnormalities, impaired liver 
function, etc., (3) drug-related arrythmia, (4) multiple drug-drug interactions, and (5) 
respiratory depression.44 Pharmacist involvement in hospice interdisciplinary teams is highly 
endorsed, with medication reconciliation one of their roles and responsibilities in hospice and 
palliative care setting. This understanding assists in using their clinical judgment to provide 
methadone recommendations, keeping its indications and contraindications in mind. Therefore, 
the strategy of obtaining pharmacists recommendation on methadone utilization will be useful 
in demonstrating the medication’s use in this setting. Moreover, evaluating the acceptance of 
these recommendations will provide information on the impact of pharmacists’ 
recommendations in hospice and palliative care setting.  
a. Study sample  
 
The sample of patients for the first part of this study included adults (18+ years old) admitted 
to hospices served by DeltaCareRx. These patients were newly admitted between October 2019 
to December 2019.  
b. Protection of human subjects  
 
The study did not involve any direct interactions with patients (and therefore posed minimal 
risk); therefore, it was granted an exemption by the IRB review. Patient information was 
protected by usage of anonymized study ID to identify patients on research documents, 
corresponding to a unique patient ID used onsite at DeltaCareRx. A master sheet matching the 
study ID and DeltaCareRx patient ID was accessible only by DeltaCareRx staff and remained 
onsite at the facility. An additional master sheet was maintained onsite to keep a record of the 
forms filled out by pharmacists, including the names of pharmacists and numbers of forms they 
were assigned (e.g. the patients they collected). 
c. Developing instruments for data collection 
 
1. Instrument #1 - Pharmacist data collection tool 
 
Preliminary literature search aided in identification of important variables in pain 
management.44,69,70 The following area were chosen to characterize and evaluate methadone 
recommendations for pain management: (1) demographics of the patient, (2) type of pain 
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(classified as nociceptive, neuropathic or both), (3) pain intensity at the admission (measured 
on a numerical scale 1=no pain to 10=worst pain), (4) current pain medication regimen, 
prescribed at the time of admission to hospice/palliative care at DeltaCareRx, (5) previous 
recommendations of methadone, (5) breakthrough medications used in past,  (6) indications 
for prescribing methadone, and (7) contraindications of prescribing methadone. The list of 
indications and contraindications are included in Table 1. If the pharmacist provided a 
recommendation for methadone, they were requested to specify the type of recommendation, 
including: (1) switch to methadone as maintenance treatment, (2) addition of methadone as 
adjunctive/adjuvant treatment, (3) discontinue methadone previously prescribed, or (4) other. 
These criteria were used to develop instrument #1, available in Appendix 1. 
 
Table 1. List of indications and contraindications of using methadone  
Indications  Contraindications  
High opioid tolerance Clinically unstable 
Refractory to other opioids Limited prognosis (< 5 days) 
Morphine allergy Drug interactions 
Severe renal impairment QTc prolongation/structural heart disease 
Neuropathic pain Severe liver impairment 
 
Substance use disorder  
Use of other long-acting CNS depressants 
 
 
2. Instrument #2 - Researcher data collection tool 
 
This data collection tool was utilized to evaluate whether the patients who had 
recommendations for methadone were accepted or not, and to collect further data on these 
patients. All new admission patients from the first phase of data collection who acquired 
recommendations from the pharmacist were followed up by a student pharmacist. The 
instrument also collected additional patient information including: (1) allergies, (2) 
comorbidities, (3) hepatic/renal dysfunction recorded as presence or absence of these 
conditions or any clinical value if provided, (4) nutritional status was recorded as it, (5) pain 
medication history of the patient prior to admission in hospice/palliative care at DeltaCareRx, 
and (6) pain intensity prior to and during the admission to DeltaCareRx setting, classified on a  
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categorical scale moderate to severe, and (7) number of days of  interval from the day of 
admission to the date of filling the instrument #2. This gave an idea of the number of days 
patients were admitted to the service. Further, if the recommendation was accepted by the 
physicians, questions exploring the therapeutic regimen were explored in the tool. Additional 
data was collected regarding which day of the week the recommendation was provided in order 
to understand site and staff’s functionality over a week’s time. Further, data on interval of days 
passed from the day of recommendation to implementation was collected. The alignment of 
the accepted dose/frequency with the pharmacist recommended dose/frequency was assessed 
through this tool if mentioned. A copy of instrument #2 is available in Appendix 2.  
 
The instruments underwent various revisions before use for data collection. Discussions with 
DeltaCareRx staff  helped in getting insights on availability of the information for completion 
of instrument #2. The revisions included additional questions related to patient’s clinical 
characteristics. The palliative prognosis scores (PPS) of the patients at the time of admission 
and during completing instrument #2, it was measured on a numerical scale 0=death to 
100=normal. It is used to predict patient’s prognosis and survival.71 A PPS is assigned based 
on  patient’s total bed bound time, extent of diseases, ability to carry out self-care, food intake 
and conscious level72. Morphine milligram equivalents (MME)73 patient was on during and 
prior to the admission was evaluated through addition of respective questions. The MME 
conversion factor was used to calculate the total opioid dosage prescribed to the 
patients.(conversion scale included in instrument #2. Appendix 2). Additionally, a question 
exploring the day of the week when recommendation was provided was also added in the tool. 
This assisted in assessing facility functionality based on the days of the week.  
d. Data collection process 
 
The data collection took place from October to December 2019 at DeltaCareRx. A total of four 
pharmacists and a student pharmacist collected data using the tools in paper format. A 
researcher designed the instruments for data collection and analyzed the collected data. All 
newly admitted patients to DeltaCareRx care underwent their usual clinical review by 
pharmacists at DeltaCareRx. After this, the four pharmacists filled out instrument #1 for each 
patient they processed. Later in the data collection, information from instrument #1 was used 
for follow-up if a recommendation for methadone was rendered. The patients who had 
instrument #1 filled, a student pharmacist filled out instrument #2 for those patients using data 
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available in the DeltaCareRx system. The student pharmacist calculated MME of the 
medications that were administered by the patients on their individual forms. Additionally, 
patients provided with a methadone recommendation had the acceptance section filled on 
instrument #2. All paper instruments contained a top section listing the DeltaCareRx patient 
ID and study ID (both necessary to achieve follow-up); this section was trimmed off prior to 
leaving the DeltaCareRx site to ensure anonymization, and then were sent to Duquesne 
University for analysis. The information from both the tools was transferred to a Microsoft 
Excel spreadsheet.  
e. Data management and statistical analysis  
 
The data from this phase was analyzed using SPSS Statistics 25 (IBM Corp; Armonk, NY). 
The individualized data collected for most variables was categorized to ease analysis. 
Examples of these categorization is provided in Appendix 3. Selected variables were 
categorized as follows. Age was classified in two classes, < 60 and ≥ 60, for the purpose of 
statistical analysis. The classification was made because majority of the patients admitted in 
hospice care are between the age 60 and higher5. Classes for terminal diagnosis/indication 
were: (1) cancer, (2) dementia, (3) cardiovascular, (4) respiratory, (5) liver, (6) kidney, (7) 
neurodegenerative, and (8) other. Classes for pain medications (prior to and at the time of 
admission) were: (1) opioid, (2) NSAID, (3) opioid/APAP, (4) gabapentin, and (5) other. 
Allergies were categorized as: (1) opioid, (2) antibiotic, (3) topical, and (4) other. 
Comorbidities included: (1) cancer, (2) dementia, (3) cardiovascular, (4) respiratory, (5) liver, 
(6) kidney, (7) endocrine, (8) psychiatric, (9) gastrointestinal, (10) neurological, and (11) other. 
The response to nutritional status was categorized as: (1) very poor, (2) poor, (3) good, (4) fair, 
and (5) good. Similarly, renal, and hepatic dysfunction was categorized as: (1) yes, (2) no, or 
(3) not known.  Recoding of string variable into numerical characters was done using the 
transform function on SPSS. Character string variables like sex (F=1, M=2), methadone 
recommendation (Y=1, N=2), acceptance of recommendation (Y=1, N=2) and type of pain 
(1=nociceptive, 2=neuropathic or 3=both) were recoded to numerical string. 
1. Research questions  
 
Research question 1: To identify the prevalence of clinical pharmacist recommendations and 




Descriptive statistics was utilized to calculate the prevalence of the methadone 
recommendation provided to the patients. Additionally, demographic, and clinical 
characteristics was evaluated for the patient sample such as patient’s mean age, height, weight, 
BMI, and sex. Standard deviation, median, maximum, and minimum values were calculated 
for these variables. Individual frequencies were measured for clinical characteristics such as 
hospice type, pain intensity, medications, palliative prognosis scores. Range was calculated for 
days from the date of admission variable. Prevalence was calculated using frequency 
evaluation of questions regarding (1) pharmacist recommendations, and (2) acceptance of the 
provided recommendations.  
 
Research questions 2: To evaluate the differences in demographic and clinical characteristic 
of patients provided with a methadone recommendation and patients who were not.  
 
Inferential statistics was utilized to evaluate the difference between the study sample 
recommended for methadone and patients who were not. The groups were compared using 
independent t-test analysis for continuous variables and Chi square test analysis for categorical 
variables.  
 
II. Phase II of the study  
 
a. Phase aim 
 
To identify the frequency in the use and monthly expenditure of three categories of 
medications: pain, pulmonary and anticoagulants at various DeltaCare Rx client sites. The 
use of the medications was stratified as per the therapeutic class of their medication 
category and sex of the patient across a pharmacy claims database.  
b. Overview 
 
Medication utilization data for six months (January, June, July, September, October and 
November) of the year 2019 was obtained from  DeltaCareRx. The data consist of month 
wise prescription drug information, including date of claim, drug names, quantity, cost, 
days of supply, and patient sex. Frequency in use, total expenditure and monthly average 
cost was calculated for each therapeutic class belonging to the three medication categories. 
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The data was stratified based on the different therapeutic class and patient’s sex. The total 
cost for each stratified subgroup was calculated. Additionally, consumption of each 
medication from the medication categories of interest were retrospectively evaluated from 
the database.  
c. Rationale 
 
Hospice and palliative care providers are assisted by DeltaCareRx in cost containment. 
DeltaCareRx uses a unique Rx purchasing model to achieve this for their clients. They 
obtain the medications from the pharmacy at highly discounted rates and provide them to 
their client with transparency in their pricing. The prescription drug data is generated 
through Deltalytics, which reports monthly utilization of medications by the hospice and 
palliative care providers.  
 
DeltaCareRx staff articulated categories of interest for the analysis, including the selected 
three broad categories of pain, pulmonary and anticoagulants. The selection was made 
because of the high medication utilization and expenditure belonging to these three-
medicine categories at all the hospice care sites served by DeltaCareRx .Therefore, the 
analysis aimed to identify the highly utilized and costly drugs from those medication 
categories. The evidence generated will be useful in cost/utilization optimization and 
developing strategies of utilizing cost effective drugs by the hospice providers served by 
DeltaCareRx. 
d. Data source  
 
Prescription claims data  was obtained from a pharmacy benefit manager, DeltaCareRx. 
The organization provides services to hospice and palliative care clients. The data includes 
unique prescription claim of the medications dispensed to a patient at the setting. 
e. Database structure  
 
Full prescription drug data for January, June, July, September, October, November months 
of the year 2019 was obtained from DeltaCareRx and made available to the researcher in 
Microsoft Excel via multiple sheet downloads. The six months for data analysis were 
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selected because of availability of complete data for these months and to maintain 
uniformity in utilization data. These multiple sheets were merged together and named. The 
primary identifiers in the dataset were the prescription number and unique identification 
number of each patient. The data set also includes other variables such as drug name, 
therapeutic class (generic and standard), quantity, average wholesale price (AWP), 
DeltaCareRx cost, days of supply, patient sex, and denotation of new/refill medication. The 
variables for the study were defined as below. 
 
 
The month-wise data sheets differed in content, with not all datasets inclusive of all 
variables.   
1. Therapeutic classification of drugs  
 
There were two (standard and generic) therapeutic class variables present in the data. For 
the present analysis, generic therapeutic classes of drugs were taken into consideration. 
There were 445 different generic therapeutic classes of medications utilized at different 
client sites of DeltaCareRx for the dataset provided.  
2. Drug names  
 
Drug names are the prescribed medications dispensed to hospice patients at DeltaCareRx 
client sites. The data includes information 3189 medications.  
3. Sex 
 
The data includes the sex of patients who were administered each medication. As per the 
information in data two nomenclatures were used to describe sex of the patients. Numerical 
‘1’ was coded for males and ‘2’ was coded for females in some of the data sheets and others 
had letters ‘M’ and ‘F’ to denote sex of the patients.  
4. Generic long name 
 
Each drug had a generic long name provided in the data. This information was useful in 
segregating the drugs based on their generic names, and not the drug names, which had a 
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high degree of variability. For example, the generic long name, ‘methadone’ had various 
drug names in the database such as “methadone 5mg”, “methadone solution 5mg/ml”, 
“methadone con 10mg/ml”. 
5. DeltaCareRx medication cost  
 
Each prescription in the database was associated with the cost charged to the patients. This 
was the cost charged by DeltaCareRx while dispensing the medications to the patients. 
f. Utilization of medications  
 
To assess the trends in utilization of medication of interest at DeltaCareRx client sites, a 
unit measurement called ‘defined daily dose (DDD)’ was used. The World Health 
Organization’s definition for DDD is “the assumed average maintenance dose per day for 
a drug used for its main indication in adults.”74 Drug utilization data presented in DDDs 
gives a rough estimate of consumption of medications. Each medication has a DDD 
assigned as per its route of administration provided it has a designated Anatomical 
Therapeutic Chemical (ATC) Classification code. ATC codes classify the active 
ingredients of medications according to the organ or system they act on and their 
therapeutically, pharmacological, and chemical properties.75 These codes are maintained 
by WHO Center for Drug Statistical Methodology. There are no DDDs assigned for topical 
products, vaccines, antineoplastic agents, allergen extracts, general and local anesthetics, 
and contrast media.74 The recommendations of average maintenance doses are made 
depending on: (1) the recommended dose referring to a body weighing 70 kg, (2) the 
maintenance dose not differing from an initial dose, (3) an assignment based on the content 
(strength) of a product, with different salts of a product not having different DDDs, and (4) 
prodrugs and various dosage forms of a same drug not having been assigned a separate 
DDD value.  
 
The trends in consumption of medications from three broad classes, (1) pain, (2) pulmonary 
and (3) anticoagulants were evaluated. A list of medications was prepared with their 
assigned DDD values referenced from the ATC/DDD Index 2020 website (Appendix 4).76 
DDD dispensed was calculated for each medication if it had the following information, (1) 
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quantity of medication, (2) strength of medication, and (3) DDD value. The formula for 
DDD dispensed used was: 
 
𝐷𝐷𝐷𝐷𝐷𝐷 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 = 𝑄𝑄𝑄𝑄𝑄𝑄𝑑𝑑𝑄𝑄𝑑𝑑𝑄𝑄𝑄𝑄 𝑜𝑜𝑜𝑜 𝑑𝑑𝑝𝑝𝑜𝑜𝑑𝑑𝑄𝑄𝑝𝑝𝑄𝑄 ∗ 𝑑𝑑𝑄𝑄𝑝𝑝𝑑𝑑𝑑𝑑𝑛𝑛𝑄𝑄ℎ/𝐷𝐷𝐷𝐷𝐷𝐷/𝑑𝑑𝑄𝑄𝑄𝑄𝑑𝑑 𝑑𝑑𝑑𝑑 𝑚𝑚𝑜𝑜𝑑𝑑𝑄𝑄ℎ  
g. Selection of medication categories  
 
Researchers categorized the relevant therapeutic class of medications from the database 
into three medication categories. A student pharmacist reviewed the selected classes to 
avoid any errors in the selection process.  
h. Data analysis  
 
The frequency of each therapeutic class of medications and their cost was found from the 
database. Cost of each therapeutic classes was identified and compared across individual 
therapeutic classes. Next, all the therapeutic class in the three medication categories were 
stratified as per patients’ sex.  Cost per patients across their sex was identified for each 
month. SUMIF and COUNIF Excel functions were used for obtaining the stratified values 
as per sex of the patient and cost values. SPSS (Version 25.0) was used to carry out the 
descriptive statistics. The Explore function was used to calculate the mean and +/- standard 
deviation values of the costs of various therapeutic classes. For the purpose of this 
descriptive analysis, the medical categories were assigned numbers such as anticoagulant 
=1, pulmonary = 2 and pain = 3 for the purpose of this analysis. The dependent variables 
for the analysis were cost per male/female patients and independent variable was the 
numerical medication categories. It demonstrated the different monthly mean cost and the 
associated +/- standard deviation value of all the therapeutic class. 
 
Utilization of each medications with available strength and quantity values was calculated 
expressed as total DDDs dispensed. SUMIF and COUNTIF functions were used across the 
Excel workbook to calculate the strength and quantity values. Individual DDD values of 
drug names were grouped under their generic long names. These values represented the 
sum of total DDDs dispensed.  
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The missing cost and quantity data in the database were filled by imputing the missing 
values. The missing values were substituted with the average of known cost/quantity values 
for the prescription. For example, in the case of missing cost value for the drug name 
MAPAP (acetaminophen) tablet 500 mg. The average of all the available cost values for 
the same tablet was substituted in the place of the missing value. In the case of missing 
quantity values in the database. The average of the highest and the lowest quantity value 
of a particular drug name was imputed for the missing value.  
1. Impact of missing data  
 
The missing values in the datasets impacted analyses in the phase II of the study. All the 
listed generic therapeutic classes in the table were not present in all the data of the months. 
Hence, those may not be uniform. The missing values of drug names and quantities did not 
allow for DDD calculation for those drugs. Additionally, combined products were excluded 
from utilization analysis because of DDD values were unavailable. The data regarding 
patient’s sex was missing in many datasets. Therefore, the stratification analysis was not 
performed for that data. The quantity of missing data and its implication on the overall 
results is specified throughout the results of phase II.  
2. Research questions  
 
Research question 1: To identify the most frequently utilized generic therapeutic class 
and their expenditure from the medication categories of pain, pulmonary and 
anticoagulants. 
 
Descriptive statistics was utilized to identify the values to answer the research question. 
The mean average cost of each therapeutic class and the standard deviation values were 
calculated.  
 
Research question 2: To identify the pattern in medication utilization on the basis of sex 




The difference in expenditure of various therapeutic class based on the sex of the patient 
was calculated for each month.  
 
Research question 3: To identify the month wise medication consumption at DeltaCare 
sites.  
  
The WHO DDD values were identified for the identified medications from the 
therapeutic class. Consumption values for individual medications was calculated using 






CHAPTER 4: RESULTS 
 
I. Phase I of the study  
 
a. Study aims 
 
To assess the data collected to identify prevalence of pharmacist methadone recommendations 
and acceptance. Further, to evaluate the difference in the characteristics of patients provided 
with the recommendation vs those who were not.  
b. Overview  
 
Descriptive analysis resulted in generation of individual frequency tables of patient 
demographics and clinical characteristics variables. Prevalence of the provided pharmacist 
recommendation and accepted recommendations were calculated. The difference between the 
patient characteristics of patients provided with recommendations vs those who were not, 
analyzed using inferential statistical analysis.  
c. Demographic and clinical characteristics of the sample  
 
1. Sample size  
 
In total, 159 instruments #1 and #2 were filled out, with 158 (99.3%) usable forms analyzed 
based on inclusion criteria.  
2. Patient demographic variables  
 
A total of 156 (98.7%) out of 158 newly admitted patients to the facility had their age 
documented on instrument #2 (Table 2). A total of 45 (28.5%) patients were of age between 
80-89 years old, 41 (26.0%) were between 90-99 years old and 3 (1.9%) were between 100-
110 years old. Patients aged 18-59 accounted for only 12 (7.6%) of the study sample. The mean 
age for the overall sample was 79.5 years (SD: 13.8 years). The sample had a slightly higher 
proportion of females (89; 56.3%) compared to males. BMI was calculated for 125 (79.1%) 
patients based on the available height and weight variables. From the total sample, 16 (12.8%) 
were classified as obese (≥30 kg/m2), 27 (17.0%) patients were overweight (25.0-29.9 kg/m2), 
64 (51.2%) had a normal BMI (18.5-24.9 kg/m2) and 18 (14.4%) were underweight (<18.5 




3.  Patient clinical characteristic variables 
 
Hospice type data was collected through instrument #1. Hospice type information was included 
in 157 (99.3%) of the patient sample. Home hospice, for 121 (76.6%) patients, was the most 
utilized type reported (Table 2). Similarly, type of pain data was collected for 101 (63.9%) of 
patient sample. The majority of patients (62; 39.2%) reported having nociceptive pain. The 
change in palliative score was recorded from day of admission (from instrument #1) to the day 
of data collection (from instrument #2). The majority of values (141; 89.2%) had no difference 
recorded. The mean of difference of 12 was found between palliative prognosis scores pre- and 
post-admission scores. Overall, mean scores during the admission and after the admission were 
37.20 and 37.44, respectively. The mean values of morphine milligram equivalent (MME) 
during the admission and after the admission were 1131.4 and 1160.3, respectively. The 
MME/day during the admission and after the admission was found to be 37.71 and 38.67. The 
data collected from the date of admission to the date of filling out the instrument ranged from 










































Age: categorization provides distribution of elderly (≥60) patients; BMI: Body Mass Index; PPS: Palliative prognosis 




A total of 124 (78.5%) patients included data regarding pain intensity score at the time of 
admission. Most of the patients (113; 71.5%) classified their pain between the scale 1 to 6  
(Table 3). The medications used during and prior to admission were categorized into respective 
therapeutic classes. In counting the number of medications patients were administering, one 
patient may belong to more than one medication category. The most common medication 
utilized in the hospice care setting was opioids (153; 97.0%) followed by APAP (55; 35.0%). 
Similarly, most medications in the pain medication history were opioids (122; 77.2%).  
 
  








Height (m) 126 (80.0) 1.6 (0.1) 
Weight (kg) 133 (84.2) 65.6 (15.0) 
BMI (kg per m2) 125 (79.1) 23.7 (5.0) 
Age (years) 
< 60 





PPS at admission 150 (95.0) 37.2 (12.1) 
PPS after admission  147 (93.0) 37.4 (12.0) 
Hospice type 
Inpatient 


















MME prior to admission  51 (32.3) 1131.4 (2261.0) 
MME after admission  67 (42.4) 1160.3 (2332.5) 
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Table 3: Overall distribution of pain variables in patients before and after the admission  
 
APAP: Acetaminophen; NSAID: Nonsteroidal anti-inflammatory drugs; Opioid/APAP: opioid/acetaminophen  
combination 
 
In total, 95 (60.1%) of patients had their allergies documented using Instrument #2. As per the 
categorization, the most frequent allergy was antibiotics (47; 23.6%) followed by opioids (31; 
15.3%). Although 97% of the sample was administering opioids for their treatment, alternative 
opioids outside of their specific allergy may have been utilized for pain management. The 
allergic conditions were opioid specific and alternate opioids were administrated for pain 
management respectively (Table 4). Similarly, in total 147 (93.0%) of patients had their 
comorbidities documented. The comorbidities were categorized as per different disease 
 n (%) 
Pain intensity before admission 
Mild  
Moderate 

























































conditions. The most common comorbidity encountered among the study sample was 
cardiovascular disease (116; 73.4%).  
 
Table 4: Overall distribution of allergies and comorbidities in study sample     


















GI: gastrointestinal; *one patient may be categorized in more than one class  
 
d. Research question 1 
1. Provided methadone recommendations  
 
In total, 37 (23.4%) patients had a methadone recommendation provided by the pharmacists. 
The majority (26; 16.5%) of reasons of methadone recommendation was switching to 
methadone as the maintenance treatment. Further, other reasons included addition of 
methadone as adjunctive treatment (7; 4.4%) and other potential reason listed by the 
pharmacists (3; 1.9%). 
2. Indications/contraindication of provided methadone recommendations  
 
The recommendations provided were based on the patient’s indication and/or contraindication 
for administering methadone. In total, 50 (31.6%) out of 158 patients had indications for 
recommending methadone reported. One patient may have one or more indications or 




























  53 (33.5) 










contraindications listed on the tool. The most common indication for methadone was identified 
as neuropathic pain (27; 17.0%) (Table 5). Contraindications were documented for 68 (43.0%) 
patients. QTc prolongation/structural heart disease was one of the most common 
contraindications for methadone (38; 24.0%) (Table 5). 
 



















CNS: Central nervous system; QTc: Corrected QT interval 
 
3. Accepted methadone recommendations  
 
Out of the 37 pharmacist recommendations, 6 (16.21%) were accepted by the physicians and 
2 (8.10%) were implemented by the physicians themselves. Most recommendations provided 
by pharmacists and physician implemented were provided on Thursday (13; 8.2%).  
e. Research question 2 
1. Sample stratification  
 
Two groups compared for the inferential analysis were patients provided with pharmacist 
methadone recommendation (37; 23.4%) and those with no methadone recommendation (121; 
76.5%). 
Indications/contraindications n (%) 
Indications  
Neuropathic pain 
Severe renal impairment 
Morphine allergy 
Refractory to other opioids 
High opioid tolerance 
Other 













Severe liver impairment 
Use of other long-acting CNS depressants 
Drug interactions 
Limited prognosis (<5 days) 












2. Methadone recommendations by demographic/clinical characteristics  
 
As per the independent t-test analysis, there was a significant difference in pharmacist 
methadone recommendations based on the patient’s pain intensity score (p<0.05). Patients with 
a high pain intensity score received higher numbers of methadone recommendations compared 
to patients with lower pain intensity scores (Table 6). 
 










Age 81.0 (13.3) 74.6 (14.4) -2.362 0.091 
BMI 24.0 (5.0) 23.0 (5.0) -1.020 0.310 
Pain intensity score 3.0 (1.9) 5.1 (1.5) 6.527 <0.05* 
PPS at admission 36.5 (12.0) 39.4 (13.4) 1.241 0.217 
PPS after admission 37.0 (12.0) 39.6 (13.0) 1.249 0.214 
Days from admission 20.0 (20.0) 28.2 (35.0) 1.362 0.181 
 
* Significant results (>0.05), PPS: Palliative prognosis score; SD: Standard deviation  
 
As per the Chi-square analysis, there was a significant difference between hospice type, 
terminal indication category, pain type, indication of methadone and whether the pharmacist 
provides methadone recommendation or not (p<0.05). The majority (34; 91.9%) of patients 
who had an acceptance for methadone recommendation received home hospice service. Cancer 
patients received higher numbers (25; 67.6%) of methadone recommendations for pain 
management as compared to other terminal diagnosis. Patients who had both nociceptive and 
neuropathic type of pain had higher number (16; 43.2%) of methadone recommendations. The 
most common (15; 40.5%) indication for which methadone recommendation provided was 





Table 7: Differences in categorical variables based on methadone recommendation    
 






























































































High opioid  
Morphine allergy  
Refractory opioids 



















Drug interactions  
Limited diagnosis (<5) 
QTc prolongation 
Severe liver impairment  





















f. Characteristics of accepted methadone recommendation patients  
 
In total, eight (21.6%) of 32 pharmacist recommendations were accepted by the physicians. 
Assessment of the characteristics of all the eight patients in terms of their type of hospice, 
type and intensity of pain, terminal diagnosis, overall medication history, indication, and 
contraindication of using methadone is summarized in Table 8. 
 
Table 8: Characteristics of patients with accepted methadone recommendations  
 
AML: Adult acute myeloid leukemia; APAP: Acetaminophen; COPD: Chronic obstructive pulmonary diseases; HIV: 
Human immunodeficiency virus  
 
Patients with study ID 70 and 94 did not receive pharmacist methadone 
recommendations, but it was implemented by the physician themselves. All of the 
patients with accepted methadone recommendation were utilizing home hospice. In total, 
six (75%) out of eight patients had cancer as their terminal diagnosis. Most 
recommendations for methadone were under the indication of neuropathic pain 
management (4; 50%); the frequency of pain intensity scores ranging between 5-8 (75%) 
was high. The allergic conditions of these patients were either not known or were not 
classified under the categorization used in this study. The listed comorbidities of these 








diagnosis  Medication history  Indication 
52 Home Both 5 AML Opioid, APAP, Gabapentin 
Neuropathic, 
other 
54 Home Nociceptive 5 
Prostate 
cancer Opioid Other 
67 Home Nociceptive 7 Colon cancer Opioid, APAP Other 
70 Home 2 Throat cancer Opioid  
94 Home 3 Lymphoma Opioid  
100 Home Both 5 COPD Opioid Neuropathic  
152 Home Neuropathic 8 Leukemia Opioid, Gabapentin, Other Neuropathic  
153 Home Neuropathic 8 HIV Opioid  Neuropathic  
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50%) conditions. The majority (6; 75%) of the nutritional statuses of these patients was 
found to be poor.  
 
II. Phase II of the study  
 
a. Study aims  
 
To identify the frequency and expenditure of medications at various hospice and palliative 
care settings served by DeltaCareRx. The use of the medications will be evaluated as per  
therapeutic class and sex of the patient across the pharmacy claims data.  
b. Overview  
 
Individual month PBM data from DeltaCareRx sites were employed to analyze the 
therapeutic class and medication utilization. The trends in the utilization were stratified on 
patients’ sex and the therapeutic class. The cost per patient depending on their sex was 
calculated for each therapeutic class belonging to the medication categories of interest. 
Individual drug consumption was evaluated by calculating the total DDD dispensed for the 
medicines.  
c. Sample characteristics  
 
Overall, the dataset consisted of  445 therapeutic class and 3189 medication names. In total 
183,450 medications were identified from the categories of interest in the combined dataset 
of all the six months.   
d. Research question 1 
 
1. Frequency in the use and expenditure of each therapeutic class in different 
months  
 
Descriptive analyses were run using individual month pharmacy claims data to identify the 
frequency in use of medications, the total cost and monthly mean cost of each therapeutic 




i. January  
 
The total number of prescriptions identified in January was 97,260. Tables 9, 10, and 11 
show each therapeutic class's frequency, total costs, and monthly mean average cost with 
standard deviation associated with each class.  
Overall, in the case of pulmonary medications, there was 4.5% of missing cost data. The 
majority of missing cost data was for sympathomimetic medications (101; 96.2%). Table 
9 shows the frequency, total, and mean monthly cost expenditure for pulmonary 
medications in January. The average monthly cost was highest for bronchodilator-
anticholinergics medications ($171.40) and steroid inhalants ($172.89). 
Table 9. Frequency and expenditure of pulmonary medications in January  
 
The amount of cost missing data in the case of pain medication was 4.3% and the majority 
(804; 82.76%) of the cost missing data was found for opioid agonists. Table 10 
demonstrates the frequency in use and cost data for pain medications in January. The 
medications belonging to the opioid agonist therapeutic class were found to have the 
highest frequency and highest expenditure.   
 
  
Therapeutic class Frequency Total cost Monthly mean cost (SD)  
Monthly median 
cost (IQR) 
Steroid inhalants 97 $16,770.00 $172.89 ($90.57) $154.28 ($120.77) 
Sympathomimetics 2,169 $79,851.03 $38.61 ($83.43) $16.87 ($21.93) 
Xanthines 26 $2625.06 $58.33 ($50.88) $31.44 ($78.66) 
Bronchodilator-
anticholinergic 69 $11,826.80 $171.40 ($196.10) $23.0 ($411.25) 
Leukotriene modulators 41 $277.31 $6.76 ($4.19) $5.13 ($5.21) 
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Table 10. Frequency and expenditure of pain medications in January 
 
In the case of anticoagulant medication, there was missing cost data for 3.15% of 
prescriptions in the database. The majority of cost missing data was found for heparin and 
heparinoid like agents. Table 11 demonstrates the frequency in use and cost data for 
anticoagulant medications in January. The total cost and monthly average cost were higher 
for direct factor Xa inhibitors than other therapeutic classes in the medication category. 
 






Therapeutic class Frequency Total cost Monthly mean cost (SD)  
Monthly median 
cost (IQR) 
Analgesics 3,722 $16,499.11 $4.54 ($9.70) $3.21 ($2.67) 
Anesthetics  27 $171.72 $6.90 ($6.40) $6.58 ($6.02) 
Anesthetics topical 337 $8,585.59  $26.17 ($32.64) $26.13 ($19.16) 
Opioid agonists  16,448 $321,495.80  $20.41 ($31.38) $13.99 ($13.76) 
Opioid 
combinations  1,698 $37,142.27 $22.12 ($21.06) $16.26 ($15.67) 
Opioid partial 
agonists  3 $314.28 $104.80 ($46.06) $110.88 (-) 
NSAIDS  411 $4,466.11 $11.36 ($55.31) $11.36 ($4.88) 




inhibitors  123 $1,395.41 $11.43 ($32.18) $3.96 ($3.67) 
Direct factor Xa 
inhibitors 143 $27,424.42 $194.50 ($72.71) $211.03 ($39.47) 
Coumarin 
anticoagulants 220 $1239.91 $5.74 ($3.55) $4.94 ($4.41) 





The total number of prescriptions identified in June was 128,786. Tables 12, 13, and 14 
show each therapeutic class's frequency, total costs, and monthly mean average cost with 
standard deviation associated with each class.  
 
Table 12 shows the total expenditure of each class belonging to the pulmonary medication 
category. The most frequently used therapeutic class was sympathomimetics with higher 
total expenditure, and the lowest monthly mean cost. 
 
Table 12. Frequency and expenditure of pulmonary medications in June 
 
 
In the case of the pain medication category, there was 0.14% of missing cost data. The 
opioid agonist therapeutic class had the majority (39; 97.5%) of missing cost data. Table 
13 demonstrates the frequency and total expenditure with the average cost per therapeutic 
class in the pain medication category.  
 
  
Therapeutic class Frequency Total cost Monthly mean  cost (SD)  
Monthly median  
cost (IQR) 
Steroid inhalants 143 $20,944.71 $146.5 ($104.91) $135.80 ($206.52) 
Sympathomimetics 3360 $124,613.04 $37.09 ($68.59) $18.77 ($19.02) 
Xanthines 26 $1,724.29 $45.37 ($42.01) $26.07 ($39.93) 
Bronchodilator-
anticholinergic 107 $18,083.71 
$169.00 
($198.93) $20.91 ($412.09) 
Leukotriene 
modulators 41 $701.97 $7.16 ($4.96) $5.20 ($5.20) 
Nasal 
anticholinergic 6 $227.46 $37.91 ($7.00) $37.21 ($13.36) 
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Table 13. Frequency and expenditure of pain medications in June 
 
Table 14 demonstrates the frequency and total expenditure with the average cost per 
therapeutic class in the anticoagulant medication category. The total cost and monthly 
average cost were higher for Direct factor Xa inhibitors than other therapeutic classes in 
the medication category. 
 






Therapeutic class Frequency Total cost Monthly mean cost (SD)  
Monthly median 
cost (IQR) 
Analgesics 4,598 $23,111.33 $5.02 ($11.90) $3.15 ($2.18) 
Anesthetics  33 $396.83 $11.20 ($20.38) $5.13 ($6.49) 
Anesthetics topical 579 $15,449.47 $26.68 ($30.84) $17.38 ($25.0) 
Opioid agonists  18,609 $412,862.6 $22.186 ($40.21) $14.24 ($13.72) 
Opioid 
combinations  2,268 $51,164.52 $22.56 ($83.43) $16.24 ($17.31) 
Opioid partial 
agonists  7 $2,007.06 $286.81 ($119.73) $307.01 ($271.66) 
NSAIDS  726 $6,818.57 $9.39 ($16.22) $3.96 ($4.66) 






249 $2,472.34 $9.93 ($27.21) $5.15 ($3.60) 
Direct factor Xa 
inhibitors 254 $53,945.07 $212.38 ($65.94) $219.83 ($16.08) 
Coumarin 
anticoagulants 403 $2,392.38 $5.93 ($3.52) $4.96 ($3.93) 






In July, there were in total 78,273 prescriptions. Tables 14, 15, and 16 show each 
therapeutic class's frequency, total costs, and monthly mean average cost with standard 
deviation associated with each class.  
 
The data for pulmonary medication had missing cost data for 0.63% (n=14) prescriptions. 
Sympathomimetics and bronchodilator-anticholinergics have the majority of the missing 
cost data. Table 15 demonstrates the monthly mean cost for each therapeutic class and the 
standard of deviation.  
 
Table 15. Frequency and expenditure of pulmonary medications in July 
 
 
In the case of pain medications, 0.22% of cost data was missing. Medications belonging 
to the opioid agonist had the majority (31; 88.6%) of missing cost data. Table 16 shows 
the frequency, total cost, and average monthly expenditure on every therapeutic class of 




Therapeutic class Frequency Total cost Monthly mean cost (SD)  
Monthly median 
cost (IQR) 
Steroid inhalants 68 $10,611.36 $156.00 ($118.71) $138.0 ($102.4) 
Sympathomimetics 1,991 $75,933.73 $38.00 ($77.73) $18.7 ($20.39) 
Xanthines 22 $1,221.96 $56.00 ($53) $36.71 ($68.33) 
Bronchodilator-
anticholinergic 78 $11,973.79 $169.00 ($216.54) $20.91 ($413.0) 
Leukotriene 
modulators 64 $465.34 $7.00 ($5) $5.20 ($5.81) 
Nasal 
anticholinergic 1 $44.59 - - 
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Table 16. Frequency and expenditure of pain medications in July 
 
 
Table 17 demonstrates the frequency of each therapeutic class of anticoagulant medication in 
July. The total cost and month mean cost is higher for direct factor Xa inhibitors. Coumarin 
anticoagulants were found to have the lowest mean average expenditure in the month.  
Table 17. Frequency and expenditure of anticoagulant medications in July 
 
iv. September  
 
In total, 134,478 the number of prescriptions were identified in September. Tables 18, 19, 
and 20 demonstrate the frequency of each therapeutic class, total costs, and monthly mean 
average cost with standard deviation associated with each class.  
 
Therapeutic class Frequency Total cost Monthly mean cost (SD)  
Monthly median 
cost (IQR) 
Analgesics 2633 $9,894.83 $3.76 ($4.31) $3.12 ($1.95) 
Anesthetics  14 $228.80 $16.34 ($25.11) $5.13 ($12.48) 
Anesthetics 
topical 413 $12,887.99 $31.20 ($59.28) $16.80 ($24.10) 
Opioid agonists  11,060 $242,094.09 $21.94 ($37.32) $14.20 ($13.86) 
Opioid 
combinations  1,353 $29,050.80 $21.47 ($19.67) $16.80 ($16.91) 
Opioid partial 
agonists  2 $448.21 $224.10 ($108.39) $224.10 (-)  
NSAIDS  444 $3,938.72 $8.87 ($14.4) $4.36 ($5.18) 






154 $1,874.12 $12.12 ($32.93) $5.29 ($4.43) 
Direct factor Xa 
inhibitors 159 $32,307.50 $203.19 ($62.66) $219.70 ($19.70) 
Coumarin 
anticoagulants 248 $1,428.83 $5.76 ($3.56) $4.75 ($3.73) 
Heparin 88 $1,357.40 $15.43 ($51.6) $3.48 ($3.29) 
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The majority of therapeutic class utilized was found to be sympathomimetics (90.38%) 
than other therapeutic classes in the pulmonary medication category. The mean average 
cost lowest for leukotriene modulators ($9). The sympathomimetics had the highest 
frequency in use (90.30%) and expenditure ($135,346) among all the other therapeutic 
classes.  
 
Table 18. Frequency and expenditure of pulmonary medications in September  
 
In the case of pain medications, there was missing cost data for 0.11% of medications. The 
majority (25; 83.3%) of the missing cost data was found for the opioid agonist therapeutic 
class medications. Table 19 shows the frequency and mean average cost of each 
therapeutic class belonging to pain medications. Opioid partial agonists constitute the 










Therapeutic class Frequency Total cost Monthly mean cost (SD)  
Monthly median 
cost (IQR) 
Steroid inhalants 104 $20,967  $151.60 ($111.72) $155.80 ($229.11) 
Sympathomimetics 3,648 $135,846  $37.00 ($71.68) $18.80 ($19.02) 
Xanthines 32 $1,425  $45.00 ($48.81)  $21.79 ($35.46) 
Bronchodilator-
anticholinergic 137 $21,476  $160.00 ($191.44) $21.34 ($412.12) 
Leukotriene 
modulators 107 $959  $9.00 ($8.35) $5.57 ($6.48) 
Nasal 
anticholinergic 9 $374  $42.00 ($7.63) $44.60 ($11.0) 
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Table 19. Frequency and expenditure of pain medications in September  
 
 
Table 20 demonstrates the frequency of therapeutic classes in the anticoagulant medication 
category and their average monthly cost. Coumarin anticoagulants have the highest 
frequency (37%) and the lowest monthly average cost ($5.85). 
 





Therapeutic class Frequency Total cost Monthly mean cost (SD)  
Monthly median 
cost (IQR) 
Analgesics 4,655 $17,481.75  $3.75 ($4.08) $3.10 ($1.85) 
Anesthetics  24 $499.20  $20.80 ($32.16) $5.13 ($18.70) 
Anesthetics topical 729 $16,541.09  $22.69 ($26.72) $15.39 ($20.0) 
Opioid agonists  18,936 $411,022.38  $21.70 ($36.62) $14.24 ($13.70) 
Opioid 
combinations  2,369 $51,420.55  $21.70 ($19.53) $16.70 ($16.83) 
Opioid partial 
agonists  7 $1,149.78  $164.25 ($115.66) $147.46 ($42.00) 
NSAIDS  847 $8,660.30  $10.22 ($16.78) $4.43 ($5.95) 




inhibitors  258 $3,370.06  $13.06 ($32.86) $4.49 ($3.34) 
Direct factor Xa 
inhibitors 306 $61,918.32  $202.34 ($55.51) $22.58 ($20.96) 
Coumarin 
anticoagulants 411 $2,404.12  $5.85 ($3.62) $4.94 ($3.34) 





In total, there were 158,830 prescriptions identified in the month of October. Tables 21, 
22, and 23 demonstrate the frequency of each therapeutic class, total costs, and monthly 
mean average cost with standard deviation associated with each class.  
 
In the case of pulmonary medications, there was 0.9% of missing cost data found for the 
identified prescriptions. In total, 71.4% of missing cost data was populated by imputing the 
data from known values in the database for the pulmonary medications.   
 
Table 21 shows the frequency, cost of the expenditure, and average monthly cost of the 
therapeutic lasses in the pulmonary medication category of October. Sympathomimetics 
were found to have the highest frequency of use (90.36%) and the highest expenditure 
($135,846) with moderately low ($37) monthly mean cost.  
 
Table 21. Frequency and expenditure of pulmonary medications in October 
 
 
In October's pain medication prescriptions, the cost data were missing for 0.7% of the 
prescriptions. In total, 20% of missing data was filled by imputing the values from the 
existing prescription data. Table 22 shows the frequency, total cost, and monthly average 
Therapeutic class Frequency Total cost Monthly mean cost (SD)  
Monthly median 
cost (IQR) 
Steroid inhalants 197 $24,547.01 $131.26 ($87.50) $84.70 ($144.50) 
Sympathomimetics 4151 $146,610.45 $35.25 ($70.00) $17.42 ($21.14) 
Xanthines 29 $1,658.71 $57.20 ($51.22) $47.36 ($71.25) 
Bronchodilator-
anticholinergic 183 $28,578.8 $160.55 ($212.40) $21.24 ($400.13) 
Leukotriene 
modulators 109 $942.95  $9 ($8.21) $5.41 ($5.81) 
Nasal 
anticholinergic 14 $487.2 $34.80 ($4.50) $33.10 (-) 
 
 67 
cost data, which consisted of 0.58% of missing cost data. The highest frequency of use and 
expenditure was found for the opioid agonist therapeutic class.  
 
Table 22.  Frequency of use and expenditure of pain medications in October  
 
 
Table 23 demonstrates the frequency and cost data for the anticoagulant medications in the 
month of October. Direct factor Xa inhibitors were found to have the highest expenditure and 
higher monthly mean cost ($202.34) compared to other therapeutic classes in the medication 
category.  
 




Therapeutic class Frequency Total cost Monthly  mean cost (SD)  
Monthly  
median cost (IQR) 
Analgesics 5,427 $24,170.05  $3.84 ($5.35) $3.10 ($1.97) 
Anesthetics  61 $430.72 $7.55 ($9.40) $4.68 ($4.49) 
Anesthetics topical 864 $19,402.18  $22.45 ($27.88) $15.52 ($16.13) 
Opioid agonists  22,600 $475,431.75 $21.20 ($35.72) $13.45 ($14.36) 
Opioid 
combinations  2596 $58,755.08  $22.63 ($21.51) $17.71 ($17.83) 
Opioid partial 
agonists  4 $1,481.06  $370.26 ($176.98) $325.04 ($323.81) 
NSAIDS  965 $9,481.32 $9.82 ($16.00) $5.03 ($6.20) 
Therapeutic class Frequency Total cost Monthly  mean cost (SD)  
Monthly 
median cost (IQR) 
Platelet aggregation 
inhibitors  289 $4,267.05  $14.81 ($38.03) $5.29 ($3.68) 
Direct factor Xa 
inhibitors 330 $69,484.23  
$210.55 
($58.49) $220.51 ($19.83) 
Coumarin 
anticoagulants 472 $2,668.22 $5.74 ($3.57) $5.04 ($4.27) 
Heparin 193 $5,521.28 $28.90 ($75.04) $3.48 ($4.44) 
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vi. November  
 
In total, there were 134,840 prescriptions identified in the month of November. Tables 24, 
25, and 26 demonstrate the frequency of each therapeutic class, total costs, and monthly 
mean average cost with standard deviation associated with each medication category.  
 
In the pulmonary medication category, 12.3% of cost data was found to be missing for the 
prescriptions. In total (425; 25.4%) of missing cost data was filled with the help of imputing 
technique. Table 24 consists of frequency, total cost, and mean average cost from the 
pulmonary medication data, which has (337; 9.18%) of missing cost data.  The 
sympathomimetics were found to have the highest utilization and expenditure with 
moderate month mean cost.  The overall expenditure of pulmonary medications in 
November was the highest  ($200,430.90) compared to other months' data. 
 
Table 24. Frequency and expenditure of pulmonary medications in November 
 
 
In the pain medication category, (7311; 34%) of cost data was found to be missing for the 
prescriptions. From the total missing data (6045; 23.24%) of cost data was filled by 
imputing the values. Table 25 shows the values from the database, which consisted of  28% 
of missing cost data.  Opioid agonists had the highest utilization and expenditure among 
all the therapeutic classes. The analgesics medication had the lowest ($3.90) mean average 
cost value.  
Therapeutic class Frequency Total cost Monthly  mean cost (SD)  
Monthly  
median cost (IQR) 
Steroid inhalants 200 $27,697.12  $152.18 ($114.70) $137.50 ($52.85) 
Sympathomimetics 4,943 $152,986.75  $32.90 ($55.61) $19.25 ($15.22) 
Xanthines 38 $1,502.88  $44.20 ($43.87) $21.79 ($48.0) 
Bronchodilator-
anticholinergic 147 $17,395.88  $168.89 ($196.66) $21.29 ($412.39) 
Leukotriene 
modulators 130 $766.46  $7.36 ($4.93) $6.0 ($5.01) 
Nasal 
anticholinergic 2 $81.8 $41 ($6.30) - 
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Table 25. Frequency and expenditure of pain medications in November 
 
 
In the case of the anticoagulant medication category, the prescription had 60% of missing 
data for cost. The missing data filled by imputing was about 26%. A high percentage (50%) 
of missing quantity data caused higher missing cost data and a low number of imputed 
values in the database. Table 26 demonstrates the values from the database, which 
consisted of  47% of missing cost data. The majority (38.03%) of missing cost data was 
for coumarin anticoagulant’s prescriptions. Direct factor Xa inhibitors were found to have 
the highest utilization, expenditure, and mean average cost value.  
 
 
Table 26. Frequency and expenditure of anticoagulant medications in November 
 
 
Therapeutic class Frequency Total cost Monthly  mean cost (SD)  
Monthly  
median cost (IQR) 
Analgesics 6,613 $24,079.25  $3.90 ($4.31) $3.32 ($1.62) 
Anesthetics  26 $301.47  $17.73 ($29.64) $5.87 ($9.37) 
Anesthetics 
topical 1,032 $16,217.97  $23.04 ($24.70) $16.06 ($17.97) 
Opioid agonists  26,223 $478,817.92  $22.74 ($35.89) $15.22 ($12.78) 
Opioid 
combinations  3,286 $50,281.78  $22.16 ($19.98) $16.82 ($16.59) 
Opioid partial 
agonists  8 $2,231.58  $278.94 ($166.55) $231.0 ($141.11) 
NSAIDS  1,178 $7,665.50  $9.12 ($16.74) $4.30 ($5.0) 
Therapeutic class Frequency Total cost Monthly  mean cost (SD)  
Monthly  
median cost (IQR) 
Platelet aggregation 
inhibitors  269 $4123.84 $15.38 ($37.03) $5.29 ($4.31) 
Direct factor Xa 
inhibitors 461 $67,795.13  $214.54 ($69.93) $220.32 ($19.86) 
Coumarin 
anticoagulants 421 $2394.0  $6.0 ($3.36) $5.05 ($3.50) 
Heparin 128 $10,968.53  $86.36 ($169.41) $4.85 ($24.90) 
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e. Overall costs per therapeutic class in the combined dataset of all the months  
 
i. Pain medication category  
 
In total 154,576 pain medication claims were identified from the combined dataset. The 
data consisted of missing cost data (8574, 5.54%). Table 27 shows the descriptive 
statistics of pain medication category in the combined data set from all the months. 
  
Table 27. Overall cost descriptive statistics for pain medication category 
 
 
ii. Pulmonary medication category  
 
In total, 22,523 pulmonary prescription data were found in the combined dataset of all the 
months.  The data consisted of missing cost data (484, 2.15%). Table 28 shows the 










Therapeutic class Mean (SD) Median (IQR) 
Analgesics  $4.28 ($8.04) $3.16 ($2.00) 
Anesthetics  $11.77 ($20.37) $5.13 ($6.60) 
NSAIDS $9.71 ($24.54) $4.34 ($4.94) 
Opioid combinations $22.16 ($20.75) $16.48 ($16.63) 
Opioids agonists  $21.75 ($36.33) $14.24 ($13.76) 
Partial agonists  $246.21 ($230.97) $230.97 ($159.55) 
Topical anesthetics  $24.62 ($19.50) $16.53 ($19.50) 
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iii. Anticoagulant medication category 
  
In total, 6,351 pulmonary prescription data were found in the combined dataset of all the 
months.  The data consisted of missing cost data (570, 9%). Table 29 shows the 
descriptive statistics of pain medication category in the combined data set from all the 
months.  
 
Table 29. Overall cost descriptive statistics for anticoagulant medication category 
Therapeutic class Mean (SD)  Median (IQR) 
Coumarin anticoagulants  $6.00 ($3.52) $4.94 ($3.84) 
Direct factor Xa $207.75 ($63.80) $219.85 ($19.64) 
Heparin  $28.55 ($3.74) $3.74 ($4.19) 
Platelet aggregation inhibitors $13.07 ($5.29) $5.30 ($8.84) 
 
  
Therapeutic class Mean (SD)  Median (IQR) 
Bronchodilator – anticholinergic  $165.16 ($201.87) $21.28 ($412.40) 
Leukotriene modulators  $7.89 ($6.51) $5.36 ($5.81) 
Nasal anticholinergic  $37.53 ($6.61) $33.31 ($11.79) 
Steroid inhalants  $140.67 ($106.94) $137.50 ($122.56) 
Sympathomimetics  $36.04 ($69.44) $18.50 ($19.53) 
Xanthines $51.00 ($47.93) $26.07 ($68.00) 
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f. Research question 2  
 
The dataset of each month was stratified as per the patient’s sex. The cost for each subset 
was calculated. Total data of dispensed medications of interest were found for 88,601 male 
and 124,389 female patients 
1. Trends in utilization as per patients’ sex 
 
Table 30 demonstrates the stratification of frequency data as per the patient’s sex for all 
the anticoagulant medications. The patient’s sex data was missing for certain prescriptions 
in the month of January (1.7%), June (50%), and for the month of November due to 47% 
of missing cost data the expenditure was found to be lower compared to the frequency of 
the use of certain medications.  In the majority of months, the frequency of anticoagulants 
used in female patients was found to be higher. The therapeutic class most frequently used 
in all the months in male and female patients was coumarin anticoagulants. In terms of 
expenditure, direct factor Xa inhibitors constituted the highest expenditure in all the months 
for both males and females.   
 










January  271 $11,203.52  319 $19,968.23  
June 222  $12,773.13  304  $19,230.51  
July 266 $16,685.28 383 $20,282.57 
September  466 $28,061.88 652 $41,968.25 
October  583 $36,278.42  727 $47,321.07  
November  666 $31,412.59  1,003 $53,868.90  
 
 
Table 31 shows similar stratification data for patients using pain medications. The patient’s 
sex data was missing for certain prescriptions in the month of January (0.5%) and June 
(47.4%) and 25% of missing cost data for the prescriptions in November. The values for 
pain medication categories were highest for both females and males than other medication 
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categories. Female patients had a higher pain medication utilization. Opioid agonist was 
found to be the most commonly used class in both males and females. In June and July, 
opioid combinations used in females were found to form a significant part of the 
expenditure of the therapeutic class ($113,121.07 and $126,663.8). In November, female 
patients were found to be administered the highest in the number of pain medications such 
as non-steroidal anti-inflammatory drugs (805; 3%), opioid combinations (2,235; 0.9%), 
and opioid agonists (17,745; 68%). 
 










January  9,362 $161,651.25  13,171 $223,667.19  
June 5,715  $113,121.07  8,355  $154,670.72  
July 6,425 $126,663.8 9,469 $171,739.3 
September  11,252 $215,511.2 16,315 $291,263.9 
October  13,754  $258,542.05  18,865  $293,689.88  
November  15,344 $239,861.60 22,117 $310,604.4 
 
 
Table 32 demonstrates trends in all the therapeutic classes of pulmonary medication 
utilization as per the patient’s sex. The patient’s sex data was missing for certain 
prescriptions in January (1.5%) and  June (47.2%). The missing cost data (9.18%) in the 
month of November shows the cost values lower compared to the frequency in use of 
medications. Sympathomimetics were highly used in both males and females; it constituted 















January  1,050 $52,288.81  1,322 $55,591.52  
June 824  $33,681.99  1,062  $43,822.29  
July 940 $41,184.77 1,284 $59,066.00 
September  1,755 $79,736.37 2,213 $100,913.4 
October  1,954 $88,792.66  2,725 $114,032.46  
November  2,388 $87,879.98  3,072 $112,550.92  
 
 
2. The difference in mean cost per patients across individual months and all the 
months  
 
Table 33 and Table 34 demonstrate the differences in mean cost per male and female 
patients across three medical categories. The mean cost per patient values for June 
differentiate from the other months due to significant missing gender data that was 50% of 
the total anticoagulant medications, 47.4% of the total pain medications and 47% of the 
total pulmonary medications. The mean of the cost per patients were found to be higher for 
June, September, and November because of comparatively higher proportions of opioid 















Table 33. Differences in per male patient mean cost across three medical categories  
 
SD: standard deviation  
 
Table 34: Differences in per female patient mean cost across three medical categories 
 
SD: standard deviation  
 
g. Research question 3 
 
The utilization of the medications was calculated using the quantity and strength data of 




Mean cost per 
male patients 












January  $48.16 $86.54 $15.12 $8.60 $66.95 $73.05 
June $58.05 $104.54 $51.75 $112.45 $58.15 $78.50 
July $61.00 $98.47 $14.71 $12.73 $66.82 $70.49 
September $58.70 $91.12 $40.35 $60.57 $60.72 $65.65 
October  $63.44 $86.021 $14.63 $8.28 $74.84 $66.66 
November  $50.27 $64.92 $39.00 $81.56 $61.48 $64.50 
Month 
Mean cost per 



















January  $60.80 $93.66 $25.39 $27.83 $68.28 $82.54 
June $60.50 $103.33 $48.54 $78.06 $53.94 $66.62 
July $57.40 $94.65 $19.55 $16.10 $72.02 $79.92 
September $60.00 $98.76 $30.94 $44.31 $74.80 $67.15 
October  $63.60 $83.40 $11.00 $9.21 $66.31 $53.69 
November  $57.70 $66.50 $37.27 $91.24 $71.31 $74.75 
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missing for the months of January, June and July. Therefore, DDD values was calculated 
for prescriptions in the months of September, October and November.  
 
Consumption level of anticoagulants varied during the months of September, October, and 
November (Table 35). Heparin was highly consumed in all the three months (638 DDDs 
dispensed, 627 DDDs and 22,095 DDDs). Warfarin consumption level was found to be 
stable in the months of October (43 DDDs) and November (40 DDDs). The overall pattern 
in use of anticoagulants as per the PBM data was not found to be consistent.  
 
Table 35. Total anticoagulant medication DDDs dispensed 
Generic long names September October November  
apixaban  85.03 40.00 41.80 
heparin 637.73 627.93 22,095.17 
warfarin 7.00 43.00 39.75 
cilostazol 4.75 1.45 1.50 
ticagrelor  - 1.50 2.10 
rivaroxaban 28.25 15.45 16.88 
prasugrel 0.50  - 0.50 
clopidogrel 128.13 68.00 76.96 
enoxaparin 147.00 248.22 160.00 
 
 
In the case of pain medications, consumption level was seen uniform for acetaminophen 
and morphine (Table 36). Hydromorphone utilization uniformly increased from 517 DDDs 
in September to 1209 DDDs in November. Overall consumption of the following 
medications,  ibuprofen (193 DDDs), methadone (741 DDDs), Oxycodone (628 DDDs) 
and tramadol (338 DDDs),  was found to higher in September. The consumption of fentanyl 







Table 36. Total pain medication DDDs dispensed 
Generic long names  September  October  November  
APAP 626.92 489.44 520.70 
diclofenac  10.10 0.206 0.173 
ibuprofen 193.00 98.40 91.30 
indomethacin 3.01 1.12 23.6 
ketorolac 1.80 0.42  - 
meloxicam 104.15 61.52 51.36 
celecoxib 36.92 15.22 17.80 
piroxicam  -  - 0.5 
oxaprozine 13.33  - 0.66 
etodolac  3.00  - 1.00 
hydromorphone  517.22 1052.4 1209.50 
methadone 741.70 368.45 337.60 
morphine  1934.32 1095.10 1111.72 
oxycodone  628.25 355.87 362.23 
tramadol 337.64 136.36 178.11 
buprenorphine 1.67 0.043 0.003 
codeine  6.31 1.06 0.75 
fentanyl 6345.84 5.46 0.01 
 
 
Table 37 shows the comparable values of consumption for the pulmonary medications 
across the three months. Pulmonary medication like albuterol, fluticasone, ipratropium, 








Table 37. Total pulmonary medication DDDs dispensed 
Generic long names  September  October  November  
albuterol 27,534.50 13,822.40 14,793.50 
budesonide 71.00 34.35  53.00 
beclomethasone   - 0.10  - 
fluticasone  5.40 4.17 2.00 
ipratropium 575.72 217.97 242.56 
tiotropium  51.00 0.03 18.00 
theophylline 17.13 7.31 7.10 
phenylephrine  8.42 4.21  0.30 







CHAPTER 5: DISCUSSION 
 
I. Key findings  
 
The current study described the prevalence of pharmacists’ methadone recommendation 
and medication utilization in hospice and palliative care settings. Phase I of the study 
prospectively evaluated the rate of pharmacists’ methadone recommendations and their 
acceptance at DeltaCareRx’s facilities. The second phase of the study retrospectively 
assessed the frequency and expenditure of utilizing pain, pulmonary, and anticoagulants 
medication at various DeltaCareRx client sites. The primary focus of the research study 
was identifying potential ways for cost optimization at various client sites of DeltaCareRx.  
 
The results of the systematic literature review conducted in this study support the 
recommendation made by ASHP of involving clinical pharmacist in hospice and palliative 
care multidisciplinary team. Although the objective of the study was assessing medication 
utilization including methadone at DeltaCareRx’s client sites the current literature review 
answers a slightly different research question. A pilot systematic review was conducted in 
the initial stages of the study to lay the foundation of methadone use in hospice and 
palliative care settings and its cost-effectiveness properties. The literature review consisted 
of key terms such as methadone, hospice care setting,  cost, and clinical benefits. However, 
the preliminary search strategy failed to generate a higher number of evidence articles for 
the hypothesis. The archived articles demonstrated the benefits of using methadone in all 
types of pain, cancer-related pain, and its cost-effectiveness as compared to other 
opioids.45,77,78 
 
The increasing expenditure and resources used in hospice and palliative care requires cost 
savings to be generated at the hospice provider sites.79 Few of the suggested ways include 
the use of PBM services to secure lower for the prescription drugs, leveraging pharmacist 
role in the multidisciplinary team, ensure adherence to the formulary, and serving patients 
with cost-effective medications to achieve desirable outcomes.80 Cost analysis in end-of-
life care is challenging due to difficulties quantifying the quality of life concept in patients 
treated for their terminal illness. The need for cost saving in this setting requires 
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implications of various ways for cost containment.21 Therefore, the study explores the 
prevalence of cost-effective methadone medication and the overall frequency, expenditure, 
and consumption of medications at the hospice and palliative care DeltaCareRx sites. The 
methadone use results provide evidence of popularity in using the cost and clinically 
effective medication for pain management.81 The results of evaluating frequency and 
expenditure of the most population medication categories pain, pulmonary, and 
anticoagulants provide a head start to develop cost containment strategies at DeltaCareRx 
client sites.  
 
The results of phase one included the prevalence of methadone recommendation and its 
acceptance in patients admitted at DeltaCareRx’s hospice and palliative care sites. The 
pharmacist data collection tool #1 identified patients’ demographic and clinical 
characteristics. The majority of patients opted for home hospice type of care and observed 
experiencing both nociceptive and neuropathic pain. The overall prevalence and 
acceptance of methadone recommendations were too low.  
 
ASHP endorsed methadone for its use in pain relief as an effective medication use in 
hospice and palliative care. 82 Methadone use for pain relief suggests constant monitoring 
of patients and titration of doses frequently.39 Current study provides potential reasons for 
the low use of methadone in hospice and palliative care settings. The literature identifies 
two conditions for low methadone use in patients with pain, which are QTc prolongation 
and respiratory disorders.83 In the current study, QTc prolongation was one of the 
conditions found to be common among patients. In alignment with the literature, this can 
be one of the potential reasons for the low prevalence and acceptance of methadone 
recommendation.  
 
The low acceptance rates of pharmacist’s recommendations also raise a concern regarding 
awareness of methadone use for pain management. Hawely et al. explore the barriers to 
continuing methadone prescription for pain management.  Despite patients’ willingness to 
receive methadone, there were barriers to receiving the treatment. The low popularity and 
knowledge about the use of methadone among healthcare professionals contributed to its 
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low accessibility.84 According to the literature, methadone is a potential treatment for 
neuropathic pain because it is an N-methyl-D-aspartate (NMD) receptor antagonist and 
prevents monoamine reuptake.85 Results in the current study supports the effectiveness of 
methadone in this type of pain. The accepted methadone recommendation was most 
commonly accepted in patients with neuropathic pain (4 out of 8; 50%). 
  
The Medicare billing policy changes encourage hospice cost-sharing for medication 
utilization. Various measures are taken to promote the optimization of cost containment 
and quality improvement for hospice providers. One such way is episode-based payment 
models, which “gives health care providers a spending target for most types of care 
provided during a clinical episode (e.g., six months of chemotherapy, an inpatient 
admission or outpatient procedure plus most other care provided in the subsequent 90 
days). If total spending is less than the target, Medicare pays providers a bonus; if total 
spending is more than the target, Medicare recoups money from providers.”86 
 
In order to start developing cost-saving strategies for DeltaCareRx’s hospice providers, it 
was essential to study the overall utilization of the most common medication categories in 
hospice and palliative care settings. PBM claims data obtained from DeltaCareRx was 
analyzed for this purpose. Overall, the frequency of pain medication use was comparatively 
higher than that of pulmonary and anticoagulant medication categories. Opioid agonists 
were most frequently used across the months. According to literature, opioids are prevalent 
in use at hospice and palliative care sites due to pain being one of the important symptoms 
experienced by these patients.87  
 
The key findings of the analysis demonstrate the frequency in the use of therapeutic classes, 
their total and average monthly expenditure. It displays the overall expenditure between 
various classes of individual medication categories. The findings can assist in designing 
and executing a cost-saving strategy for each category. The known clinically effective but 
cost-effective medications can be used more than the expensive ones from particular 
categories. For example, the total DDDs of morphine medication dispensed is uniformly 
higher in all the months. In terms of consumption of cost-saving medications like 
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methadone was found to be as much as other opioid medications. Overall, it displays a 
comparable use of this medication among the pain medications at different hospice and 
palliative care sites of DeltaCareRx.  
 
In November, the frequency in use of pulmonary medications was the highest (5,460), and 
due to missing cost data (9.18%), the total expenditure ($200,430.81) did not align with 
the frequency. The average costs for pulmonary medications per male patients and female 
patients across all the months was found to be $64.82 and $67.77. Sympathomimetics  (like 
albuterol, ipratropium, ipratropium bromide, arformoterol) was the most commonly used 
therapeutic class. The expenditure of sympathomimetics was also found higher in all the 
months. The average cost of the overall class in all the months was between the range of 
($31-$38). This implies that the therapeutic class used in this class does not increase the 
expenditure of the overall medication category.  
 
Coumarin anticoagulants (warfarin sodium), had a uniform frequency in use across all the 
months (January – 32%, June – 32.41%, July – 38.21%, September – 38%, October – 
36.80%, November – 37.44%). The average costs for anticoagulant medications per male 
patients and female patients across all the months was found to be $56.60 and $60.00. 
Among all the therapeutic classes in the anticoagulant medication category, direct factor 
Xa medications (like rivaroxaban and apixaban) were found to have the highest monthly 
mean in all the months. Therefore, the formulary at DeltaCareRx can include cost-effective 
direct factor Xa medications to increase cost savings at the client sites.  
 
The frequency in use of opioid agonists (like morphine, fentanyl, hydromorphone, 
oxycodone, tramadol, methadone) in all the six months was high (January – 72.61%, June 
– 69.40%, July – 69.70%, September – 70.20%, October – 71.16%, November – 68.35%). 
The overall frequency of pain medication was higher, but the per male and female patient 
cost was not found to be that higher ($29.30 and $28.77). The higher prevalence of pain 
symptoms among hospice and palliative care patients increases the overall use of these 
drugs, increasing the total expenditure. The use of opioid partial agonists (like 
buprenorphine) varied throughout the months. The higher cost of the medication in this 
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therapeutic class skewed the overall monthly mean cost for September, October, and 
November. In terms of the pain medication category, any cost-effective medication used 
in any therapeutic class will help in overall cost optimization at DeltaCareRx sites. The 
results from the phase I of the study can be useful in road mapping an increase in the use 
of methadone at the client sites to increase cost savings.  
 
The prescription claims data obtained from DeltaCareRx identifies the cost savings 
associated with methadone use at client sites. Methadone belongs to the opioid agonist 
therapeutic class. In the combined data set of all the months, the overall frequency and 
expenditure of methadone was found to be 10,993 and $110,376.49. The overall frequency 
and expenditure of all other opioid agonists was found to be 48,305 and $135,79,26.494. 
Therefore, the average expenditure of using methadone ($10) was lower compared to all 
other opioid agonists ($28).  
 
The key finding of the analysis evaluating medication utilization as per sex of the patient 
demonstrated higher use of pain medication among female patients. In alignment with the 
evidence available in the literature that women patients have the higher chances of 
receiving pain medications. There are various explanation for this bais in use of pain 
management medications such as high incidence of osteoporosis among women, biological 
factors, higher adverse events of analgesic use in men compared to women and at time 
phycians’s gender also influences their clinical judgemnet of medication prescription to 
their male or female patients. 88,89 
 
Evaluation of medication consumption was evaluated using DDD values of individual 
medications in different months. The advantage of using the DDD methodology is that the 
utilization of the medications can be compared across different months in a standardized 
manner. The DDD values vary throughout due to differences in the consumption of 
medications with specific strength and quantity. This can be explained with an example 
such as warfarin consumption in September (7 DDD), October (42 DDD), and November 
(39.95 DDD). The consumption of warfarin tablets with a 7.5 mg strength was higher in 




Heparin and heparinoid-like agents such as enoxaparin were the most commonly utilized 
anticoagulant medications in all the three months. The most commonly utilized direct 
factor Xa inhibitor was apixaban and rivaroxaban. The utilization of opioid agonists was 
found to be consistent in all three months, which was followed by APAP. The utilization 
of different NSAIDs varied across the three months. Albuterol had higher consumption 
values in all three months.  
 
The major disadvantage of using DDD methodology is the difference between the 
prescribed daily dose and WHO recommended DDD. Another limitation is that the DDD 
values do not account for the potency of the drugs but depends on the frequency in use of 
the dose of each drug.90 Also, the database used for this study consisted of missing quantity 
values for the prescriptions. This influences the DDD values acquired for a particular 
medication. Additionally, the DDD values for combinations products other than products 
listed in Appendix 4 was not available on the WHO DDD website.  The database consisted 
majorly of these combination products whose consumption cannot be studied due to the 
unavailability of DDD values.  
 
II. Limitations and future considerations  
 
The study consisted of some limitations that may have impacted the results and are 
important to consider for a clear interpretation of the study results.  
 
a. Clinical outcomes of methadone use  
 
The study evaluates the prevalence and acceptance of methadone recommendations. As a 
part of future research avenues the accepted methadone recommendations can be followed 
up for clinical outcomes. The clinical benefit of methadone use can be studied by following 
the accepted patients for methadone use. A clinical trial study in patients with chronic and 
opioid dependence when treated with methadone demonstrated improvement in pain 
compared to buprenorphine.91 Methadone has clinical advantages of relieving chronic pain, 
longer half-life, safety in use despite renal and liver disease, and no active metabolites. 39 
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These treatment benefits can be identified by following the patients for their improvement 
in pain management.  
 
b. Generalizability  
 
The data for phase one was collected from selective sites of DeltaCareRx. The geographical 
location of the selected sites was not available to the researchers. The collected data was 
not from all the sites of DeltaCareRx. This bias the study results. The methadone 
recommendation might be low only at DeltaCareRx sites compared to other hospice and 
palliative care settings. A comparative study between DeltaCareRx sites and non 
DeltaCareRx hospice providers can help understand these differences in methadone use.  
 
c.  Limitation of using PBM claims database 
 
The PBM claims database did not have any lab values such as patient’s pain scores, FEV1 
values, partial thromboplastin time (PTT), etc. of the patients. Therefore, the clinical 
benefit of using the medications was not quantified. The differences in higher and lower 
consumption levels of various medications could have been aligned with the patients' 
disease condition's incidence.  
d. Impact of missing data  
 
The inclusion of data from all the months of 2019 will help evaluate the trends in the 
utilization of the medications over a year. The results based on the individual month data 
are standalone and cannot be extrapolated to the use of medications in the whole year. Also, 
geographical differences in the frequency of medication use and its costs can be valuable 
to study. The facility-based evaluation will allow exploring differences in the utilization of 
medications as per their geography.  
 
III. Study implications and conclusion  
 
Overall, the study provides evidence on the use of the pharmacist role and medication 
utilization in hospice and palliative care settings. As per ASHP inclusion of pharmacists 
does have a positive impact on the multidisciplinary hospice team. In this study, it was seen 
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that the pharmacists’ recommendation helped in increasing the probability of the use of 
cost-effective treatments like methadone. The use of methadone in hospice and palliative 
care setting is still a topic of discussion. The results of this study support the evidence of 
its low popularity of use due to various reasons. The study provides a starting point in 
understating the prevalence of methadone use in a real-world setting.  The findings from 
this research have implicated on importance of methadone use at DeltaCareRx sites and 
how can the staff be trained on its use. The frequency and monthly average cost results will 
help to develop a roadmap of increasing the use of cost-effective medications. The 
formulary provided to the hospice sites by DeltaCareRx may include medications that were 
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Appendix 1: Instrument #1 – Pharmacist Data Collection tool  
 
 
DeltaCare patient ID: ________________    Date of admission: ________________ 
 
 
Instrument #1 – Pharmacist Data Collection 
 
Duquesne study ID: _______________  
Type of hospice:  Home  Nursing home  Assisted living  Inpatient     
Terminal indications/diagnoses: ______________________________________  
Type of pain (select all that apply):   Nociceptive  Neuropathic   




Pain intensity at admission (on a scale of 1 to 10): _______ 
Palliative prognosis score at admission: _______ 
 
Which of the following potential indications for methadone use are present? (select all that apply)  
 Neuropathic pain  Morphine allergy  High opioid tolerance  Refractory to other opioids  
Severe renal impairment  Other: 
_____________________________________________________________ 
 
Which of the following contraindications/precautions for methadone are present? (select all that apply) 
 Clinically unstable  Limited prognosis (<5 days)  QTc prolongation/structural heart disease 
 Severe liver impairment  Obstructive sleep apnea  Substance use disorder  Electrolyte 
abnormalities  High fall potential  Use of other long-acting CNS depressant included in current 
medication regimen  
 Drug interactions (if so, list which one(s)): ________________________________  
 Other: _____________________________________________________________ 
 
Was a recommendation for methadone provided?  Yes  No 
 
If yes, what recommendation was provided:  
 Switch to methadone as maintenance treatment 
 Addition of methadone as adjunctive/adjuvant treatment 
 Discontinue methadone previously prescribed 









Appendix 2: Instrument #2 – Researcher Data Collection tool 
 
DeltaCare patient ID: ________________ 
 
 
Instrument #2 – Researcher Data Collection 
 
Duquesne study ID: _________________ 
Age (in years): _______________ Sex (M/F): ___________ Race/ethnicity: ___________ 
Height: ___________Weight: ___________  
Allergies: ______________________________________________ 
 
Days since hospice admission: ________          
Comorbidities: ________________________________________________________________________ 
________________________________________________________________________ 
PEG tube (Y/N):  ___________Dysphagia (Y/N): ___________  
Nutritional status: ___________________________  
Renal function: ___________ Hepatic function: ___________ 
 





Morphine milligram equivalents (MME) patient was on prior to admission: ___________ 
Pain control prior to admission:  Mild  Moderate  Severe 
 
Morphine milligram equivalents (MME) patient on currently: ________________ 
Current pain control:  Mild  Moderate  Severe    
Current palliative prognosis score: _______________ 
 
Was the pharmacist recommendation for methadone accepted?   Yes   No  NA 
If yes, what day of the week was methadone recommended? _______________ 
If yes, how many days after admission was recommendation implemented? ___________ 
 
If yes, was the dose/frequency recommended implemented?   Yes  No 











Appendix 3: Examples of categorization of variables  
 
 
Terminal indication/diagnosis  
Indication/ diagnosis category (1=cancer, 
2=dementia, 3=cardiovascular, 4=respiratory, 
5=liver, 6=kidney, 7=neurodegenerative, 8=other) 
 Sepsis 8 
 Alzheimer's 2 
 ESRD 6 
 Parkinson's 7 
 Alzheimer's 2 
 Cardiac arrhythmia  3 
 Amyloidosis 8 
 
 
Pain medication  Med category1 (1=opioid, 2=NSAID, 3=APAP, 4= gabapentinoid, 5=other) 
 Morphine  1 
 APAP 3 
 Pregabalin 4 
 Fentanyl 1 
 Oxycodone 1 
 Methyl Salicylate  5 
 Ibuprofen  2 




Allergy category (0=none, 
1=opioid, 2=antibiotic, 
3=topical, 4=other) 
 PCN 2 
 codeine, PCN, oxycodone 1, 2 
 morphine, amlodipine 1, 4 
 Crestor, sulfa 2, 4 
 Adhesive tape, nickel, morphine, 
aluminum, ASA, azithromycin, loratadine 1, 2, 3, 4 














Comorbidity category (1=cancer, 
2=dementia, 3=cardiovascular, 




 a fib, multivalvular regurgitation, CKD, hypoxemia 3, 4, 6 
 cervicalgia, carpal tunnel, oxygen dependent, 
underweight, low back pain, anxiety, GERD, chronic 
laryngitis, emphysema, hernia, HTN, resp failure 
3, 4, 8, 9, 11 
 HTN, COPD, dementia, DM2, hypothyroid 2, 3, 4, 7 
 DVT, PE, HTN, cerebral atherosclerosis  3, 10 
 clotting disorder, ascites, OA, osteopenia 3, 5, 11 




























Appendix 4: List of DDD values  
 
Medications with DDD values 
 
Inhal: Inhalation, O: Oral route of administration, P: Parenteral route of administration, N: Nasal route of 
administration, R: Rectal route of administration 
 
Pain 
NSAIDS DDD Route of administration 
celecoxib 0.2 g O 
diclofenac 0.1 g O, P, R 
etodolac  0.4 g O 
ibuprofen  1.2 g O 
indomethacin  0.1 g O 
ketorolac tromethamine  30 mg O, P 
naproxen  1.2 g O 
naproxen sodium 0.5 g O 
piroxicam  20 mg O 
meloxicam 15 mg O, P, R 
sulindac 0.4 g O, P, R 
Analgesics DDD Route of administration 
APAP 3 g O 
etodolac 0.4 g O 
acetylsalicylic acid  3 g 1 g 
O 
P 
Opioids  DDD Route of administration 
buprenorphine 1.2 g In the data 15mcg/hr (patch) 
codeine sulfate 0.1 g  


















oxycodone 75 mg 30 mg  
O 
P 
tapentadol HCl 0.4 g O 
















Inhal. Solution  
fluticasone propionate 0.2 mg N 








ipratropium bromide 0.24mg N 
tiotropium bromide 10 mcg Inhal powder 
umeclidinium bromide 55 mcg Inhal powder 
oxymetazoline HCl 0.4 mg N 
salbutamol (albuterol) 0.8 mg 10 mg 
Inhal aerosol, powder 
Inhal solution  
terbutaline sulfate 15 mg O, P 
theophylline anhydrous 0.4 g O, P, R 
tiotropium bromide 10 mcg 5 mcg 
Inhal powder 
Inhal solution  
pseudoephedrine  0.24 g O 
phenylephrine  40 mg O 
beclomethasone dipropionate 0.4 mg N 
 
 
Anticoagulants DDD Route of administration 
apixaban 10 mg O 
cilostazol 0.2 g O 
clopidogrel bisulfate 75 mg O 
enoxaparin sodium 2 TU (time unit) P 
prasugrel HCl 10 mg O 
rivaroxaban 20 mg O 
ticagrelor 0.18 g O 
warfarin sodium 7.5 mg O, P 










azelastine HCl/fluticasone propionate 
albuterol sulfate 
budesonide/formoterol fumarate 
fluticasone furoate/umeclidinium bromide/vilanterol trifenat 
fluticasone propionate/salmeterol xinafoate 
formoterol fumarate 
ipratropium bromide 








tiotropium bromide/olodaterol HCl 
umeclidinium bromide 
umeclidinium bromide/vilanterol trifenatate 
 
 
 
